<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">VMJ</journal-id>
<journal-id journal-id-type="hwp">spvmj</journal-id>
<journal-id journal-id-type="nlm-ta">Vasc Med</journal-id>
<journal-title>Vascular Medicine</journal-title>
<issn pub-type="ppub">1358-863X</issn>
<issn pub-type="epub">1477-0377</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1358863X12450094</article-id>
<article-id pub-id-type="publisher-id">10.1177_1358863X12450094</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Link between the renin–angiotensin system and insulin resistance: Implications for cardiovascular disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zhou</surname><given-names>Ming-Sheng</given-names></name>
<xref ref-type="aff" rid="aff1-1358863X12450094">1</xref>
<xref ref-type="aff" rid="aff2-1358863X12450094">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Schulman</surname><given-names>Ivonne H</given-names></name>
<xref ref-type="aff" rid="aff1-1358863X12450094">1</xref>
<xref ref-type="aff" rid="aff2-1358863X12450094">2</xref>
<xref ref-type="aff" rid="aff3-1358863X12450094">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zeng</surname><given-names>Qiang</given-names></name>
<xref ref-type="aff" rid="aff4-1358863X12450094">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-1358863X12450094"><label>1</label>Nephrology-Hypertension Section, Veterans Affairs Medical Center, University of Miami Miller School of Medicine, Miami, FL, USA</aff>
<aff id="aff2-1358863X12450094"><label>2</label>Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL, USA</aff>
<aff id="aff3-1358863X12450094"><label>3</label>Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA</aff>
<aff id="aff4-1358863X12450094"><label>4</label>International Medical Center, Chinese PLA General Hospital, Beijing, China</aff>
<author-notes>
<corresp id="corresp1-1358863X12450094">Ming-Sheng Zhou Vascular Biology Institute and Division of Nephrology and Hypertension University of Miami Miller School of Medicine Nephrology-Hypertension Section, Veterans Affairs Medical Center 1201 NW 16th Street, Room A-1009 Miami, FL 33125 USA Email: <email>mzhou2@med.miami.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>17</volume>
<issue>5</issue>
<fpage>330</fpage>
<lpage>341</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The incidence of metabolic syndrome is rapidly increasing in the United States and worldwide. The metabolic syndrome is a complex metabolic and vascular disorder that is associated with inappropriate activation of the renin–angiotensin–aldosterone system (RAAS) in the cardiovascular (CV) system and increased CV morbidity and mortality. Insulin activation of the phosphatidylinositol-3-kinase (PI3K) pathway promotes nitric oxide (NO) production in the endothelium and glucose uptake in insulin-sensitive tissues. Angiotensin (Ang) II inhibits insulin-mediated PI3K pathway activation, thereby impairing endothelial NO production and Glut-4 translocation in insulin-sensitive tissues, which results in vascular and systemic insulin resistance, respectively. On the other hand, Ang II enhances insulin-mediated activation of the mitogen-activated protein kinase (MAPK) pathway, which leads to vasoconstriction and pathologic vascular cellular growth. Therefore, the interaction of Ang II with insulin signaling is fully operative not only in insulin-sensitive tissues but also in CV tissues, thereby linking insulin resistance and CV disease. This notion is further supported by an increasing number of experimental and clinical studies indicating that pharmacological blockade of RAAS improves insulin sensitivity and endothelial function, as well as reduces the incidence of new-onset diabetes in high-risk patients with CV disease. This article reviews experimental and clinical data elucidating the physiological and pathophysiological role of the interaction between insulin and RAAS in the development of insulin resistance as well as CV disease.</p>
</abstract>
<kwd-group>
<kwd>angiotensin II</kwd>
<kwd>cardiovascular disease</kwd>
<kwd>insulin resistance</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1358863X12450094" sec-type="intro">
<title>Introduction</title>
<p>Diminished tissue sensitivity to insulin is a characteristic feature of various pathological conditions termed the metabolic syndrome, also known as the cardiometabolic syndrome. Factors that contribute to the complex interaction between genetic and environmental factors underlying impaired insulin signaling include obesity, physical inactivity, and aging.<sup><xref ref-type="bibr" rid="bibr1-1358863X12450094">1</xref></sup> Clinically, the cardiometabolic syndrome is characterized by central obesity, hypertension, hyperlipidemia, hyperinsulinemia, microalbuminuria, and endothelial dysfunction,<sup><xref ref-type="bibr" rid="bibr2-1358863X12450094">2</xref></sup> all of which are risk factors for cardiovascular (CV) and chronic kidney diseases.<sup><xref ref-type="bibr" rid="bibr2-1358863X12450094">2</xref>,<xref ref-type="bibr" rid="bibr3-1358863X12450094">3</xref></sup> Insulin resistance is central to the pathophysiology of the cardiometabolic syndrome. Increasing evidence demonstrates that insulin resistance can develop not only in tissues classically responsive to insulin, but also in CV tissues, where it participates in the development of CV disease.<sup><xref ref-type="bibr" rid="bibr4-1358863X12450094">4</xref>,<xref ref-type="bibr" rid="bibr5-1358863X12450094">5</xref></sup></p>
<p>The cardiometabolic syndrome is a complex metabolic and vascular syndrome that is associated with CV activation of the renin–angiotensin–aldosterone system (RAAS) and oxidative stress as well as a substantial risk for CV and chronic kidney diseases.<sup><xref ref-type="bibr" rid="bibr5-1358863X12450094">5</xref></sup> RAAS is an endocrine system predominantly responsible for the regulation of systolic blood pressure as well as salt and water homeostasis. Angiotensin (Ang) II, however, has many actions beyond its effects on blood pressure and has been shown to inhibit insulin signaling.<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref>,<xref ref-type="bibr" rid="bibr7-1358863X12450094">7</xref></sup> Indeed, insulin and Ang II are two important hormones in the control of metabolic and hemodynamic homeostasis, respectively. Functional interaction between Ang II and insulin is operative in insulin-sensitive tissues as well as the CV system, and participates in the regulation of metabolism and CV function.<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref>,<xref ref-type="bibr" rid="bibr8-1358863X12450094">8</xref>,<xref ref-type="bibr" rid="bibr9-1358863X12450094">9</xref></sup> The evidence of a link between insulin resistance and an inappropriately overactive renin–angiotensin system (RAS)has been implicated in the pathogenesis of hypertension, obesity, and type II diabetes mellitus (T2DM).<sup><xref ref-type="bibr" rid="bibr10-1358863X12450094">10</xref>,<xref ref-type="bibr" rid="bibr11-1358863X12450094">11</xref></sup> A growing number of experimental and clinical studies<sup><xref ref-type="bibr" rid="bibr12-1358863X12450094">12</xref>,<xref ref-type="bibr" rid="bibr13-1358863X12450094">13</xref></sup> have provided evidence indicating that pharmacological blockade of the RAAS by either angiotensin-converting enzyme (ACE) inhibitors or angiotensin II type 1 receptor blockers (ARBs) not only reduces CV injury but also improves insulin sensitivity and reduces the incidence of new onset T2DM in subjects with hypertension and/or CV disease, independently of blood pressure-reducing effects.</p>
<p>This review focuses on: (1) the CV actions of insulin; (2) the association between inappropriate activation of RAAS and insulin resistance in the development of CV diseases; and (3) experimental and clinical evidence supporting the role of RAAS blockade in the prevention and treatment of metabolic and CV diseases.</p>
</sec>
<sec id="section2-1358863X12450094">
<title>Cardiovascular actions of insulin</title>
<p>Insulin has important vascular effects that contribute to either vascular protection or injury (<xref ref-type="fig" rid="fig1-1358863X12450094">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr14-1358863X12450094">14</xref></sup> In the vascular endothelium, insulin stimulates two major signaling transduction cascades: the phosphatidylinositol-3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) pathways.<sup><xref ref-type="bibr" rid="bibr15-1358863X12450094">15</xref></sup> Among the most important CV actions and vasoprotective effects of insulin is the stimulation of nitric oxide (NO) production in the endothelium.<sup><xref ref-type="bibr" rid="bibr16-1358863X12450094">16</xref></sup> It is clear that insulin stimulates endothelial NO production via activation of the PI3K pathway, which phosphorylates and activates Akt, which in turn phosphorylates and activates endothelial nitric oxide synthase (eNOS), resulting in increased NO production.<sup><xref ref-type="bibr" rid="bibr16-1358863X12450094">16</xref></sup> On the other hand, insulin also promotes a host of deleterious vascular effects by stimulating the actions of various growth factors acting through stimulation of the MAPK pathway, leading to vasoconstriction and proatherogenic effects.<sup><xref ref-type="bibr" rid="bibr4-1358863X12450094">4</xref></sup></p>
<fig id="fig1-1358863X12450094" position="float">
<label>Figure 1.</label>
<caption>
<p>Insulin actions and insulin signaling pathways in the cardiovascular system. Insulin, after binding its receptor, stimulates two signaling cascades: insulin receptor substrate-1 (IRS-1)/phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK). Downstream events of phospho-Akt include: (1) stimulation of Glut-1 (vascular cells) or Glut-4 (skeletal muscle, liver and fat tissues) translocation into membrane, which mediates insulin’s metabolic effects; and (2) phosphorylation of endothelial nitric oxide synthase (eNOS) and production of nitric oxide (NO), which induces vasorelaxation and anti-inflammatory and antiatherogenic effects. Insulin activation of MAPK promotes vascular smooth muscle cell (VSMC) proliferation/migration and release of endothelin-1 (ET-1), which induces pro-atherogenic and vasoconstriction effects. In the heart, insulin increases coronary blood flow through stimulation of eNOS/NO production and promotes cardiomyocyte hypertrophy through phosphorylation of Akt and activation of MAPK.</p>
</caption>
<graphic xlink:href="10.1177_1358863X12450094-fig1.tif"/></fig>
</sec>
<sec id="section3-1358863X12450094">
<title>Hemodynamic actions of insulin</title>
<p>In the CV system, insulin contributes to hemodynamic regulation by multiple mechanisms.<sup><xref ref-type="bibr" rid="bibr14-1358863X12450094">14</xref></sup> Vasodilation is one of the most important vascular actions of insulin. It has been shown that insulin induces vasodilation in arteries and veins, leading to increased microcirculatory flow via increased capillary recruitment, through stimulation of endothelial NO production.<sup><xref ref-type="bibr" rid="bibr12-1358863X12450094">12</xref>,<xref ref-type="bibr" rid="bibr16-1358863X12450094">16</xref></sup> For instance, insulin infusion at higher physiological concentrations under euglycemic glucose clamp conditions causes a dose-dependent increase in blood flow to skeletal muscle.<sup><xref ref-type="bibr" rid="bibr17-1358863X12450094">17</xref></sup></p>
<p>Vasodilator responses to insulin-stimulated NO production comprise two distinct stages. First, insulin dilates the terminal arterioles to increase capillary recruitment without concomitant changes in total limb blood flow. This is subsequently followed by relaxation of larger resistance arteries and leads to increased limb blood flow.<sup><xref ref-type="bibr" rid="bibr18-1358863X12450094">18</xref></sup> Animal and human studies have shown that vasodilation leading to increased blood flow in the skeletal muscle is a major physiological consequence of the insulin-stimulated PI3K-eNOS pathway, leading to increased NO production in the endothelium, which may contribute to increased glucose disposal.<sup><xref ref-type="bibr" rid="bibr16-1358863X12450094">16</xref></sup> The NO-dependent vasodilator effects of insulin are antagonized by the vasoconstrictor effects of insulin mediated by activation of the sympathetic nervous system and stimulation of the secretion of the vasoconstrictor endothelin-1 (ET-1) in the vascular endothelium.<sup><xref ref-type="bibr" rid="bibr19-1358863X12450094">19</xref>,<xref ref-type="bibr" rid="bibr20-1358863X12450094">20</xref></sup> In healthy humans, the acute physiological and pharmacological concentration of insulin increases venous plasma catecholamine concentrations and sympathetic outflow in the skeletal muscle.<sup><xref ref-type="bibr" rid="bibr12-1358863X12450094">12</xref>,<xref ref-type="bibr" rid="bibr19-1358863X12450094">19</xref></sup> Another biological action of insulin that may impact hemodynamic homeostasis is stimulation of ET-1 release from the endothelium.<sup><xref ref-type="bibr" rid="bibr20-1358863X12450094">20</xref></sup> ET-1 is a potent vasoconstrictor. Insulin induces ET-1 release via stimulation of the MAPK pathway, as evidenced by the finding that MAPK inhibition blocks the vasoconstrictor effects of insulin.<sup><xref ref-type="bibr" rid="bibr20-1358863X12450094">20</xref></sup> Thus, insulin exerts opposing vasodilator and vasoconstrictor actions with negligible net effect on blood pressure in normal individuals. However, in states of insulin resistance, such as obesity and T2DM, there is impairment in insulin-stimulated NO production and activation of the sympathetic system due to chronic hyperinsulinemia, which shifts the balance in favor of vasoconstriction, thereby promoting hypertension and CV disease.<sup><xref ref-type="bibr" rid="bibr12-1358863X12450094">12</xref></sup></p>
</sec>
<sec id="section4-1358863X12450094">
<title>Anti-inflammatory and atheroprotective effects of insulin</title>
<p>It has been shown that insulin at physiological concentrations has anti-inflammatory and anti-atherogenic effects via stimulation of NO production in the endothelium.<sup><xref ref-type="bibr" rid="bibr21-1358863X12450094">21</xref></sup> NO is an important vasoprotective molecule and the endothelium is the first organ that insulin encounters after it is secreted into the circulation. It has been shown that NO induces vasodilation and inhibits vascular smooth muscle cell migration and proliferation, inflammatory cell infiltration into the vascular wall, and platelet aggregation, all of which contribute to the atheroprotective effect of insulin.<sup><xref ref-type="bibr" rid="bibr22-1358863X12450094">22</xref></sup> Therefore, constitutive stimulation of NO production by insulin may play a crucial role for maintenance of vascular health under physiological conditions. Indeed, recent evidence shows that insulin exerts vasodilatory, anti-platelet and anti-inflammatory effects at the cellular level in vitro and in vivo.<sup><xref ref-type="bibr" rid="bibr23-1358863X12450094">23</xref><xref ref-type="bibr" rid="bibr24-1358863X12450094"/>–<xref ref-type="bibr" rid="bibr25-1358863X12450094">25</xref></sup> In Apo E-deficient mice, insulin administration reduced the number and the size of atherosclerotic lesions.<sup><xref ref-type="bibr" rid="bibr26-1358863X12450094">26</xref></sup> Infusions of low doses of insulin to obese subjects significantly reduced reactive oxygen species (ROS) and plasma levels of inflammatory cytokine markers, including intracellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator inhibitor-1 (PAI-1).<sup><xref ref-type="bibr" rid="bibr21-1358863X12450094">21</xref>,<xref ref-type="bibr" rid="bibr27-1358863X12450094">27</xref></sup> Furthermore, a low dose of insulin infusion that did not lower plasma glucose concentration markedly improved clinical outcomes in patients with acute myocardial infarction, accompanied by a significant reduction in plasma C-reactive protein, an index of systemic inflammation.<sup><xref ref-type="bibr" rid="bibr28-1358863X12450094">28</xref></sup></p>
<p>Heme oxygenase (HO)1 is an important antioxidant molecule that has been shown to protect against oxidative injury in atherogenesis.<sup><xref ref-type="bibr" rid="bibr29-1358863X12450094">29</xref>,<xref ref-type="bibr" rid="bibr30-1358863X12450094">30</xref></sup> Insulin increases HO1 expression in vitro and in vivo through activation of the PI3K/Akt pathway.<sup><xref ref-type="bibr" rid="bibr31-1358863X12450094">31</xref>,<xref ref-type="bibr" rid="bibr32-1358863X12450094">32</xref></sup> Moreover, insulin upregulation of HO1 prevented H<sub>2</sub>O<sub>2</sub>-induced nuclear factor-κB (NFκB) and caspase-8 activation and apoptosis in pericytes.<sup><xref ref-type="bibr" rid="bibr31-1358863X12450094">31</xref></sup> Therefore, upregulation of HO1 may be another mechanism underlying the anti-inflammatory and atheroprotective effects of insulin.</p>
</sec>
<sec id="section5-1358863X12450094">
<title>Proinflammatory and proatherogenic effects of insulin</title>
<p>Insulin is a growth factor that regulates several proto-oncogene transcriptional factors, including c-fos and MAPK.<sup><xref ref-type="bibr" rid="bibr33-1358863X12450094">33</xref></sup> The growth-stimulating effects of insulin may importantly contribute to increased CV risk. Obese individuals and those with T2DM are at a greater risk of developing atherosclerosis than the rest of the population.<sup><xref ref-type="bibr" rid="bibr34-1358863X12450094">34</xref></sup> The underlying mechanisms may involve compensatory hyperinsulinemia in these subjects.<sup><xref ref-type="bibr" rid="bibr35-1358863X12450094">35</xref></sup> Evidence from human and animal studies have shown that compensatory hyperinsulinemia resulting from insulin resistance stimulates expression of PAI-1, vascular cell adhesion molecule-1 (VCAM-1), and E-selectin via a MAPK-dependent mechanism, which may contribute to accelerated atherosclerosis.<sup><xref ref-type="bibr" rid="bibr36-1358863X12450094">36</xref></sup> In addition, recent studies have shown that insulin increases expression of arterial angiotensinogen and angiotensin type 1 (AT<sub>1</sub>) receptor in cultured vascular smooth muscle cells.<sup><xref ref-type="bibr" rid="bibr37-1358863X12450094">37</xref>,<xref ref-type="bibr" rid="bibr38-1358863X12450094">38</xref></sup> Increased AT<sub>1</sub> receptor by insulin may be another mechanism by which hyperinsulinemia promotes the development of CV diseases in obese and type II diabetic individuals with insulin resistance.</p>
</sec>
<sec id="section6-1358863X12450094">
<title>Regulation of cardiac function by insulin</title>
<p>Insulin participates in the regulation of cardiac metabolism, growth, contractility, and coronary blood flow. Insulin regulates metabolism in the heart by modulating glucose transport, glycolysis, glycogen synthesis and lipid metabolism.<sup><xref ref-type="bibr" rid="bibr14-1358863X12450094">14</xref></sup> A normal heart derives approximately 70% of its energy from fatty acids, whereas the failing heart shifts its metabolic profile to glucose, instead of fatty acids, as the primary energy substrate.<sup><xref ref-type="bibr" rid="bibr39-1358863X12450094">39</xref></sup> The metabolic actions of insulin are mediated through a PI3K-dependent pathway, which stimulates Akt phosphorylation and Glut-4 translocation to the membrane, thereby facilitating glucose uptake.<sup><xref ref-type="bibr" rid="bibr40-1358863X12450094">40</xref></sup> Myocardial insulin resistance involving the metabolic pathway results in a number of changes in the signaling cascade that lead to inhibition of insulin-mediated phosphorylation of insulin receptor substrate-1 (IRS-1) tyrosine residues and a specific impairment of the PI3K pathway.<sup><xref ref-type="bibr" rid="bibr40-1358863X12450094">40</xref></sup> Signaling through the IRS-1/PI3K/Akt pathway is also essential for developmental and physiological growth of the heart.<sup><xref ref-type="bibr" rid="bibr14-1358863X12450094">14</xref></sup> Constitutive overexpression of Akt leads to cardiac hypertrophy and dysfunction. Pathological cardiomyocyte hypertrophy is regulated by a subset of signaling pathways including insulin activation of PI3K/Akt and MAPK pathways.<sup><xref ref-type="bibr" rid="bibr41-1358863X12450094">41</xref></sup> Insulin increases cardiac contractility through activation of L-type Ca<sup>2+</sup> channels, leading to increased Ca<sup>2+</sup> influx into cardiac myocytes.<sup><xref ref-type="bibr" rid="bibr42-1358863X12450094">42</xref></sup> Insulin enhancement of cardiac contractility increases myocardial work and oxygen consumption, resulting in a compensatory increase in coronary blood flow. In healthy subjects, insulin enhances myocardial blood flow and decreases coronary vascular resistance. The underlying mechanisms involve stimulation of NO production in the endothelium.<sup><xref ref-type="bibr" rid="bibr14-1358863X12450094">14</xref></sup></p>
</sec>
<sec id="section7-1358863X12450094">
<title>Activation of RAAS</title>
<p>RAAS plays an important role in the regulation of physiological processes of the CV system. It is an enzymatic cascade that starts with the cleavage of angiotensinogen by renin to form the inactive decapeptide Ang I. Thereafter, Ang I is converted by ACE to form Ang II. Alternatively, a recently identified carboxypeptidase, ACE2, cleaves one amino acid from either Ang I or Ang II, decreasing Ang II levels and increasing Ang 1–7,<sup><xref ref-type="bibr" rid="bibr43-1358863X12450094">43</xref></sup> which has vasodilator properties. Thus, the balance between ACE and ACE2 is an important factor regulating Ang II levels. The major biologically active products of the RAAS are Ang II and aldosterone. Ang II acts on both AT<sub>1</sub> and AT<sub>2</sub> receptors. The AT<sub>1</sub> receptor is ubiquitously and abundantly distributed in adult tissues, including blood vessels, heart, kidney, adrenal gland, liver, brain, and lung. The AT<sub>1</sub> receptor mediates all the classic and well-known effects of Ang II, such as elevation of blood pressure, vasoconstriction, increase in cardiac contractility, aldosterone release from nerve endings, an increase in renal sodium and water reabsorption, and Ang II-induced growth in CV and renal tissues.<sup><xref ref-type="bibr" rid="bibr22-1358863X12450094">22</xref></sup> Aldosterone is a steroid hormone with mineralocorticoid activity that is produced mainly by the adrenal glomerulosa in response to Ang II. The best known physiological role of aldosterone is to increase sodium reabsorption in the distal nephron to maintain sodium balance via activation of the apical epithelial sodium channel and the basolateral Na<sup>+</sup>, K<sup>+</sup>-ATPase. Beyond its effects on sodium reabsorption, aldosterone exerts effects on the kidney, blood vessels and the heart, which can have pathophysiological consequences.<sup><xref ref-type="bibr" rid="bibr44-1358863X12450094">44</xref></sup> The circulating RAAS participates in the short-term regulation of the CV system. It becomes activated in acute conditions, including hypotension, hypovolemia, and hemorrhage. In chronic conditions, including hypertension and heart failure, activation of the RAAS participates in the long-term regulation of CV homeostasis via sustained activation of local angiotensin and degradation of bradykinin, resulting in permanent CV structural changes.<sup><xref ref-type="bibr" rid="bibr22-1358863X12450094">22</xref>,<xref ref-type="bibr" rid="bibr45-1358863X12450094">45</xref></sup></p>
<p>Upregulation of RAAS has been found in the CV system in T2DM individuals, which may contribute to the development of many diabetic CV complications, including microvascular and macrovascular diseases.<sup><xref ref-type="bibr" rid="bibr4-1358863X12450094">4</xref></sup> Hyperglycemia increases transcription of angiotensinogen and Ang II production from the local ACE. Obesity, a common cause of insulin resistance, is associated with upregulation of RAAS in adipose tissue, which may trigger chronic inflammatory processes, resulting in insulin resistance.<sup><xref ref-type="bibr" rid="bibr46-1358863X12450094">46</xref>,<xref ref-type="bibr" rid="bibr47-1358863X12450094">47</xref></sup></p>
</sec>
<sec id="section8-1358863X12450094">
<title>The interaction of RAAS and insulin signaling in the CV system</title>
<p>Insulin and Ang II are two important hormones in the control of metabolic and hemodynamic homeostasis, respectively.<sup><xref ref-type="bibr" rid="bibr7-1358863X12450094">7</xref>,<xref ref-type="bibr" rid="bibr8-1358863X12450094">8</xref></sup> Recent studies have suggested that the signal transduction pathways of insulin and Ang II share a number of downstream effectors and cross-talk at multiple levels<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref></sup> (<xref ref-type="fig" rid="fig2-1358863X12450094">Figure 2</xref>). Insulin signaling is initiated by circulating insulin binding to its receptor. The insulin receptor is a heterotetrameric tyrosine kinase that after binding insulin undergoes a rapid tyrosine autophosphorylation that activates the receptor kinase and allows transient interaction with IRS-1. Interaction of tyrosine phosphorylated IRS-1 with PI3K results in PI3K activation and Akt phosphorylation, which stimulates translocation of Glut-4 to the sarcolemma to facilitate glucose uptake and NO production in the endothelium to induce vasorelaxation.<sup><xref ref-type="bibr" rid="bibr17-1358863X12450094">17</xref></sup></p>
<fig id="fig2-1358863X12450094" position="float">
<label>Figure 2.</label>
<caption>
<p>Interaction of insulin and angiotensin (Ang) II in cardiovascular (CV) and metabolic diseases. Metabolic or CV risk factors stimulate the renin–Ang system to increase production of reactive oxygen species (ROS). ROS activate redox-sensitive inflammatory signaling pathways such as nuclear factor κB to increase production of proinflammatory cytokines, which induce phosphorylation of insulin receptor substrate-1 (IRS-1) at serine residues (Ps), then inhibit insulinstimulated phosphorylation of IRS-1 at tyrosine residues (Pt), and consequently inhibit insulin signaling through the phosphatidylinositol 3-kinase (PI3K) pathway, resulting in insulin resistance, hyperinsulinemia, type II diabetes mellitus (T2DM) and metabolic diseases. On the other hand, Ang II/ROS activates the mitogen-activated protein kinase (MAPK) pathway to induce vascular remodeling, which promotes CV disease.</p>
</caption>
<graphic xlink:href="10.1177_1358863X12450094-fig2.tif"/></fig>
<p>Ang II has been shown to inhibit the insulin-PI3K signaling pathway in both vascular and skeletal muscle cells.<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref>,<xref ref-type="bibr" rid="bibr48-1358863X12450094">48</xref></sup> In cultured L6 myocytes, Ang II stimulates serine-phosphorylation of IRS-1.<sup><xref ref-type="bibr" rid="bibr49-1358863X12450094">49</xref></sup> IRS-1 is one of the major substrates of the insulin receptor kinase and contains multiple tyrosine phosphorylation motifs that serve as docking sites for SH2 domains that mediate the metabolic and growth-promoting functions of insulin.<sup><xref ref-type="bibr" rid="bibr7-1358863X12450094">7</xref></sup> IRS-1 also contains over 30 potential serine/threonine phosphorylation sites. Phosphorylation of IRS-1 at serine/threonine inhibits insulin stimulation of tyrosine phosphorylation, resulting in inhibition of downstream insulin signaling molecules.<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref></sup> It has been shown that phosphorylation of IRS-1 at Ser<sup>612</sup> (human Ser<sup>616</sup>) and Ser<sup>307</sup> (human Ser<sup>312</sup>) inhibits the insulin/PI3K signaling pathway.<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref></sup> The phosphorylation of IRS-1 at Ser<sup>612</sup> causes dissociation of the p85 subunit of PI3K, inhibiting downstream signaling, whereas the phosphorylation of IRS-1 on Ser<sup>307</sup> results in its dissociation from the insulin receptor and triggers proteasome-dependent degradation.<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref></sup> Ang II induces serine phosphorylation at both sites and inhibits downstream signaling, including Akt phosphorylation, Glut-4 translocation to the sarcolemma, and NO production in endothelium.<sup><xref ref-type="bibr" rid="bibr6-1358863X12450094">6</xref>,<xref ref-type="bibr" rid="bibr7-1358863X12450094">7</xref></sup> Studies in the TG(mREN2)27 rat model, which harbors the mouse <italic>Ren-2</italic> renin gene and is a transgenic model with elevation of systemic and tissue Ang II levels,<sup><xref ref-type="bibr" rid="bibr50-1358863X12450094">50</xref></sup> have shown that these rats exhibit whole-body and skeletal muscle insulin resistance, associated with enhanced ROS production and defective activation of the IRS-1/PI3K signaling pathway.<sup><xref ref-type="bibr" rid="bibr51-1358863X12450094">51</xref>,<xref ref-type="bibr" rid="bibr52-1358863X12450094">52</xref></sup> Furthermore, the antioxidant tempol improved insulin-mediated glucose uptake in the skeletal muscle of this animal model,<sup><xref ref-type="bibr" rid="bibr51-1358863X12450094">51</xref></sup> suggesting that Ang II impairs insulin sensitivity at least in part through generation of ROS.</p>
<p>In the vasculature, insulin stimulates two major signaling transduction cascades: PI3K and MAPK.<sup><xref ref-type="bibr" rid="bibr4-1358863X12450094">4</xref></sup> Insulin stimulation of NO production through activation of the PI3K pathway leads to vasodilation and increased blood flow, and subsequent augmentation of glucose disposal in skeletal muscle.<sup><xref ref-type="bibr" rid="bibr4-1358863X12450094">4</xref></sup> NO is an important vasoprotective molecule. In physiological conditions, constitutive stimulation of NO production by insulin may play an important role in the maintenance of vascular health as well as regulation of glucose metabolism.<sup><xref ref-type="bibr" rid="bibr22-1358863X12450094">22</xref></sup> Insulin also stimulates the MAPK pathway in the vascular endothelium, which mediates cellular growth and migration as well as production of prothrombotic and profibrotic factors.<sup><xref ref-type="bibr" rid="bibr35-1358863X12450094">35</xref></sup> The level of insulin necessary for stimulation of MAPK and PI3K may differ.<sup><xref ref-type="bibr" rid="bibr35-1358863X12450094">35</xref></sup> Fasting plasma insulin levels in a normal insulin-sensitive individual are usually in the low picomolar range (50–150 pM). At this range, insulin constitutively stimulates the PI3K pathway, which participates in the regulation of the metabolic effects of insulin and maintenance of vascular tone. In insulin-resistant states, such as obesity and diabetes, fasting insulin levels may reach the nanomolar range and are often associated with activation of RAAS. In addition, insulin-stimulation of the PI3K pathway is selectively impaired.<sup><xref ref-type="bibr" rid="bibr35-1358863X12450094">35</xref></sup> Overactivation of RAAS and hyperinsulinemia may synergistically stimulate the MAPK pathway, which exerts detrimental effects on the vascular wall by inducing endothelial dysfunction and promoting atherosclerosis.<sup><xref ref-type="bibr" rid="bibr4-1358863X12450094">4</xref></sup> Several clinical and experimental studies<sup><xref ref-type="bibr" rid="bibr1-1358863X12450094">1</xref>,<xref ref-type="bibr" rid="bibr53-1358863X12450094">53</xref><xref ref-type="bibr" rid="bibr54-1358863X12450094"/>–<xref ref-type="bibr" rid="bibr55-1358863X12450094">55</xref></sup> have shown that inhibition of RAAS by either ACE inhibitors, ARBs, or mineralocorticoid receptor (MR) antagonists improve insulin signaling and insulin sensitivity, indicating an important role of RAAS in impaired insulin signaling. However, several clinical studies have failed to demonstrate any beneficial effects of ARBs on insulin resistance.<sup><xref ref-type="bibr" rid="bibr56-1358863X12450094">56</xref><xref ref-type="bibr" rid="bibr57-1358863X12450094"/>–<xref ref-type="bibr" rid="bibr58-1358863X12450094">58</xref></sup> The reasons for this discrepancy may include differences in study design and/or study populations, and suggest the involvement of complex mechanisms underlying the interaction between RAAS and insulin resistance.</p>
</sec>
<sec id="section9-1358863X12450094">
<title>RAAS, insulin resistance and obesity</title>
<p>Obesity is a common cause of insulin resistance and one of the strongest risk factors for the development of T2DM as well as CV diseases.<sup><xref ref-type="bibr" rid="bibr59-1358863X12450094">59</xref></sup> Many studies suggest that obesity is associated with a systemic chronic inflammatory response characterized by altered proinflammatory cytokine production and activation of inflammatory signaling pathways in adipose tissue.<sup><xref ref-type="bibr" rid="bibr47-1358863X12450094">47</xref>,<xref ref-type="bibr" rid="bibr60-1358863X12450094">60</xref></sup> It is increasingly recognized that adipose tissue does not only store energy, but acts as an active endocrine and paracrine organ that produces and releases a large number of cytokines and bioactive mediators, referred to as adipocytokines, that regulate insulin signaling.<sup><xref ref-type="bibr" rid="bibr61-1358863X12450094">61</xref></sup> The inflammatory cytokines or diabetogenic adipokines are mostly produced from pre-adipocytes (undifferentiated adipocytes), whereas differentiated adipocytes produce antidiabetic adipocytokines, such as adiponectin.<sup><xref ref-type="bibr" rid="bibr62-1358863X12450094">62</xref>,<xref ref-type="bibr" rid="bibr63-1358863X12450094">63</xref></sup> The adipocytes express all components of RAS, including angiotensinogen, ACE, AT<sub>1</sub>, and AT<sub>2</sub> receptors.<sup><xref ref-type="bibr" rid="bibr62-1358863X12450094">62</xref></sup> Experimental studies have provided evidence showing that Ang II inhibits adipogenic differentiation of human adipocytes via the AT<sub>1</sub> receptor, resulting in increased secretion of inflammatory cytokines or diabetogenic adipokines, leading to inhibition of insulin signaling and insulin resistance.<sup><xref ref-type="bibr" rid="bibr64-1358863X12450094">64</xref></sup> It has been proposed that blockade of RAAS may promote the recruitment and differentiation of pre-adipocytes and increased formation of small insulin-sensitive adipocytes, thereby improving insulin sensitivity.<sup><xref ref-type="bibr" rid="bibr46-1358863X12450094">46</xref></sup> In the OLEFT rat, an animal model with T2DM, Lee et al.<sup><xref ref-type="bibr" rid="bibr46-1358863X12450094">46</xref></sup> showed that treatment with an ARB improved the differentiation of adipocytes and inhibited activation of the inflammatory process in adipose tissue, accompanied by an increase in adiponectin and a decrease in NFκB, PAI-1, and MCP-1.</p>
</sec>
<sec id="section10-1358863X12450094">
<title>RAAS, insulin resistance and salt-sensitive hypertension</title>
<p>Hypertension and T2DM are two powerful risk factors for development of CV disease. The salt sensitivity of blood pressure and insulin resistance have been identified as key factors underlying the relationship between hypertension and T2DM.<sup><xref ref-type="bibr" rid="bibr1-1358863X12450094">1</xref>,<xref ref-type="bibr" rid="bibr65-1358863X12450094">65</xref></sup> Excess dietary salt and caloric intake, as commonly found in westernized diets, is linked not only to increased blood pressure, but also to impaired insulin sensitivity and glucose homeostasis.<sup><xref ref-type="bibr" rid="bibr1-1358863X12450094">1</xref></sup> A recent clinical study<sup><xref ref-type="bibr" rid="bibr66-1358863X12450094">66</xref></sup> has shown that the insulin resistance syndrome enhances the blood pressure response to sodium intake. Thus, a reduction in sodium intake could be an important component in reducing blood pressure in patients with multiple risk factors for the insulin resistance syndrome.</p>
<p>There is a strong clustering of markers of endothelial damage in individuals predisposed to salt-sensitive hypertension who concomitantly have insulin resistance and microalbuminuria.<sup><xref ref-type="bibr" rid="bibr67-1358863X12450094">67</xref></sup> Clinical studies have demonstrated that the salt sensitivity of blood pressure is an independent risk factor for increased CV morbidity and mortality in normotensive and hypertensive individuals.<sup><xref ref-type="bibr" rid="bibr67-1358863X12450094">67</xref></sup> Salt-sensitive hypertensive patients account for about 50% of hypertensives and have a higher incidence of left ventricular hypertrophy, endothelial dysfunction, hyperlipidemia, and microalbuminuria compared with salt-resistant hypertensive patients.<sup><xref ref-type="bibr" rid="bibr68-1358863X12450094">68</xref></sup> The Dahl salt-sensitive (DS) rat is an animal model of low-renin salt-sensitive hypertension in humans, characterized by CV disease and insulin resistance. Using this model, we and others have shown that salt-sensitive hypertension is a vascular diathesis characterized by impairment of endothelial NO-dependent vasorelaxation, upregulation of vascular tissue Ang II action, and ROS production, as well as susceptibility to CV and renal injury.<sup><xref ref-type="bibr" rid="bibr69-1358863X12450094">69</xref>,<xref ref-type="bibr" rid="bibr70-1358863X12450094">70</xref></sup> Moreover, we have shown that the hypertensive DS rats manifest metabolic insulin resistance, determined by hyperinsulinemic euglycemic clamp, impaired endothelium-dependent relaxation to insulin (vascular insulin resistance), and impaired insulin signaling through the PI3K/Akt/NO pathway, associated with increased vascular and systemic inflammatory responses.<sup><xref ref-type="bibr" rid="bibr9-1358863X12450094">9</xref>,<xref ref-type="bibr" rid="bibr71-1358863X12450094">71</xref></sup> Treatment with the ARB candesartan or the antioxidant tempol improved metabolic insulin sensitivity and insulin-mediated vasorelaxation (<xref ref-type="fig" rid="fig3-1358863X12450094">Figure 3</xref>) via insulin-mediated stimulation of NO production, suggesting that Ang II-mediated ROS overproduction interferes with insulin signaling pathways in both metabolic and CV tissues in this hypertensive animal model.<sup><xref ref-type="bibr" rid="bibr9-1358863X12450094">9</xref></sup></p>
<fig id="fig3-1358863X12450094" position="float">
<label>Figure 3.</label>
<caption>
<p>Effects of angiotensin type 1 receptor blocker (ARB) and antioxidant tempol on insulin-mediated vasorelaxation (A) and glucose disposal (B: glucose infusion rate) in Dahl salt-sensitive (DS) rats. DS rats were fed normal salt (0.5% NaCl, NS), high salt (4% NaCl, HS), HS plus ARB candesartan (10 mg/kg/day in drinking water, HS/ARB), or HS plus tempol (172 mg/l in the drinking water, HS/Temp) for 6 weeks. Endothelium-dependent relaxation to insulin in the aorta was determined using an organ chamber bath. Glucose infusion rate, an index of insulin sensitivity, was determined by hyperinsulinemic-euglycemic clamp. Insulin-induced vasorelaxation was significantly impaired in the aorta of hypertensive rats and was restored by either ARB or tempol treatment (A). The glucose infusion rate required to maintain plasma glucose at 5.5 mmol/l during the insulin-infusion period was also significantly reduced in hypertensive DS rats and significantly improved with ARB or tempol treatment (B), suggesting that Ang II and ROS is involved in impaired systemic and vascular insulin resistance. The data are expressed as mean ± SEM; *<italic>p</italic> &lt; 0.05 vs HS; <italic>n</italic> = 6–7.</p>
</caption>
<graphic xlink:href="10.1177_1358863X12450094-fig3.tif"/></fig>
</sec>
<sec id="section11-1358863X12450094">
<title>RAAS, insulin resistance and endothelial dysfunction</title>
<p>The endothelium represents a single layer of cells that line all the vessels in the body, including the conduit and resistance vessels, precapillary arteries, and capillaries. The vascular endothelium regulates local vasomotor tone, local homeostasis, and vascular wall proliferation processes via release/synthesis of numerous vasoactive factors referenced as endothelium-derived factors. Endothelium-derived NO is a well characterized relaxing factor that contributes to the overall regulation of arterial blood pressure by virtue of its ability to relax vascular smooth muscle.<sup><xref ref-type="bibr" rid="bibr72-1358863X12450094">72</xref></sup></p>
<p>Insulin resistance and endothelial dysfunction are two major components of the metabolic syndrome.<sup><xref ref-type="bibr" rid="bibr73-1358863X12450094">73</xref></sup> Endothelial dysfunction, characterized by reduced NO bioavailability, contributes to CV disease, including hypertension, atherosclerosis, and coronary artery disease, which are also characterized by insulin resistance.<sup><xref ref-type="bibr" rid="bibr12-1358863X12450094">12</xref></sup> In the context of the vascular system, insulin resistance manifests as impaired vasodilation, microvascular disease (i.e. retinopathy, neuropathy, and nephropathy), and enhanced vascular inflammation and atherosclerotic lesion formation.<sup><xref ref-type="bibr" rid="bibr4-1358863X12450094">4</xref></sup> Thus, impairment of insulin action in the vascular endothelium may be a link between hemodynamic and metabolic dysfunction in obesity and T2DM4. Indeed, obese individuals with insulin resistance and patients with T2DM have impaired insulin-stimulated activation of PI3K. In these patients, endothelium-dependent relaxation in response to insulin as well as acetylcholine is often blunted.<sup><xref ref-type="bibr" rid="bibr74-1358863X12450094">74</xref></sup></p>
<p>Accumulating clinical and experimental evidence indicates that activation of the RAS plays an important role in the development of endothelial dysfunction and insulin resistance in CV diseases and T2DM.<sup><xref ref-type="bibr" rid="bibr46-1358863X12450094">46</xref>,<xref ref-type="bibr" rid="bibr75-1358863X12450094">75</xref></sup> Activation of RAS has been shown to be related to impaired insulin signaling and systemic insulin resistance in numerous tissues, including skeletal muscle and liver, as well as cardiac, vascular, and renal tissues.<sup><xref ref-type="bibr" rid="bibr48-1358863X12450094">48</xref>,<xref ref-type="bibr" rid="bibr49-1358863X12450094">49</xref></sup> Studies in humans have demonstrated a significant association between insulin resistance and hypertension, which might be mediated by RAAS activation and oxidative stress.<sup><xref ref-type="bibr" rid="bibr67-1358863X12450094">67</xref>,<xref ref-type="bibr" rid="bibr76-1358863X12450094">76</xref></sup> It is well established that activation of RAAS contributes to endothelial dysfunction through increased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived ROS mechanisms in hypertension and other CV diseases.<sup><xref ref-type="bibr" rid="bibr77-1358863X12450094">77</xref></sup> Hypertension and T2DM are also associated with a decreased number and impaired function of endothelial progenitor cells (circulating bone marrow-derived stem cells that play an important role in vascular wall endothelial repair).<sup><xref ref-type="bibr" rid="bibr78-1358863X12450094">78</xref></sup> Inhibition of the RAAS increases the number and function of endothelial progenitor cells in patients with stable coronary artery diseases as well as in subjects with T2DM.<sup><xref ref-type="bibr" rid="bibr78-1358863X12450094">78</xref>,<xref ref-type="bibr" rid="bibr79-1358863X12450094">79</xref></sup> Indeed, clinical and experimental studies have demonstrated that ACE inhibitors, ARBs, MR blockers and antioxidants improve endothelium-dependent vasodilation, arterial structure, as well as insulin sensitivity in diabetic and hypertensive patients and animals, highlighting an important role of RAAS and ROS in the induction of vascular diseases and impaired insulin sensitivity.<sup><xref ref-type="bibr" rid="bibr49-1358863X12450094">49</xref>,<xref ref-type="bibr" rid="bibr77-1358863X12450094">77</xref>,<xref ref-type="bibr" rid="bibr80-1358863X12450094">80</xref></sup></p>
</sec>
<sec id="section12-1358863X12450094">
<title>RAAS blockade in the clinical setting</title>
<p>The effects of RAAS blockade with ACE inhibitors and ARBs have been studied extensively in patients with hypertension, congestive heart failure, coronary artery disease, and chronic kidney disease.<sup><xref ref-type="bibr" rid="bibr11-1358863X12450094">11</xref>,<xref ref-type="bibr" rid="bibr81-1358863X12450094">81</xref></sup> RAAS inhibition has been shown to improve insulin resistance and glucose intolerance in non-diabetic patients with CV disease or CV risk factors, as well as improve CV and renal outcomes in diabetic patients.<sup><xref ref-type="bibr" rid="bibr56-1358863X12450094">56</xref>,<xref ref-type="bibr" rid="bibr80-1358863X12450094">80</xref>,<xref ref-type="bibr" rid="bibr82-1358863X12450094">82</xref>,<xref ref-type="bibr" rid="bibr83-1358863X12450094">83</xref></sup> In addition, results from several large randomized clinical trials, including VALUE,<sup><xref ref-type="bibr" rid="bibr84-1358863X12450094">84</xref></sup> NAVIGATOR,<sup><xref ref-type="bibr" rid="bibr85-1358863X12450094">85</xref></sup> ALLHAT,<sup><xref ref-type="bibr" rid="bibr86-1358863X12450094">86</xref></sup> HOPE,<sup><xref ref-type="bibr" rid="bibr87-1358863X12450094">87</xref></sup> CAPPP,<sup><xref ref-type="bibr" rid="bibr88-1358863X12450094">88</xref></sup> CHARM,<sup><xref ref-type="bibr" rid="bibr89-1358863X12450094">89</xref></sup> SOLVD<sup><xref ref-type="bibr" rid="bibr90-1358863X12450094">90</xref></sup> and LIFE,<sup><xref ref-type="bibr" rid="bibr91-1358863X12450094">91</xref></sup> suggest that ACE inhibitors and ARBs reduce the incidence of new-onset T2DM (NOD) in high-risk patients with CV disease.</p>
<p>The VALUE trial was designed to compare CV outcomes in treatment regimens based on the ARB valsartan and the calcium channel blocker amlodipine in a population of essential hypertensive patients recruited according to a specific predefined age- and risk factor-dependent algorithm. A total of 15,245 high-risk patients were followed for an average of 4.2 years. The results showed that there was no difference between the two drug regimens in the primary composite cardiac endpoint rate or in all-cause mortality.<sup><xref ref-type="bibr" rid="bibr84-1358863X12450094">84</xref></sup> However, the relative risk of NOD, a pre-specified secondary end point, was 23% lower in the group receiving valsartan than in the amlodipine group.<sup><xref ref-type="bibr" rid="bibr55-1358863X12450094">55</xref>,<xref ref-type="bibr" rid="bibr84-1358863X12450094">84</xref>,<xref ref-type="bibr" rid="bibr92-1358863X12450094">92</xref></sup></p>
<p>The findings from the VALUE trial showing that RAAS inhibition prevents the development of NOD have been supported by a number of other clinical studies.<sup><xref ref-type="bibr" rid="bibr85-1358863X12450094">85</xref>,<xref ref-type="bibr" rid="bibr86-1358863X12450094">86</xref></sup> The NAVIGATOR trial demonstrated that treatment with the ARB valsartan during an average of 5 years, in addition to lifestyle modifications, reduced the progression to T2DM in a large group of patients with impaired glucose tolerance and established CV disease.<sup><xref ref-type="bibr" rid="bibr85-1358863X12450094">85</xref>,<xref ref-type="bibr" rid="bibr93-1358863X12450094">93</xref></sup> A meta-analysis of 13 randomized trials was done to determine if ACE inhibitors and/or ARBs prevent the development of T2DM.<sup><xref ref-type="bibr" rid="bibr94-1358863X12450094">94</xref></sup> These trials enrolled 92,408 patients without T2DM, of whom 41,950 were randomized to treatment with an ACE inhibitor or ARB, while the remainder received active control (calcium channel blockers (CCBs), thiazide diuretics, or β-blockers) or placebo. RAAS inhibition resulted in a 27% reduction in the relative risk of NOD in nine of these trials with hypertensive patients, and a 33% reduction of NOD in four of the trials with patients with vascular disease or left ventricular dysfunction. On the other hand, in the DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial,<sup><xref ref-type="bibr" rid="bibr95-1358863X12450094">95</xref></sup> the ACE inhibitor ramipril was not associated with a significant reduction in development of NOD compared with placebo. However, ramipril significantly increased regression to normoglycemia relative to placebo administration, suggesting a beneficial effect of RAAS blockade on glucose homeostasis.</p>
<p>Patients with T2DM have a high risk of development of CV complications. Several recent large CV outcome trials conducted among patients with T2DM have demonstrated that intensive glycemic control with traditional anti-diabetic agents failed to lower the risk of incident CV diseases.<sup><xref ref-type="bibr" rid="bibr96-1358863X12450094">96</xref><xref ref-type="bibr" rid="bibr97-1358863X12450094"/><xref ref-type="bibr" rid="bibr98-1358863X12450094"/>–<xref ref-type="bibr" rid="bibr99-1358863X12450094">99</xref></sup> The lack of CV benefit of traditional anti-diabetic agents may be due to their inability to decrease CV inflammation,<sup><xref ref-type="bibr" rid="bibr100-1358863X12450094">100</xref></sup> which is mechanistically linked to the development of CV disease and the metabolic syndrome. ACE inhibition and ARBs exert modest effects on glycemia but significant inhibitory effects on systemic and/or local (renal, CV, adipose, and skeletal muscle) inflammation and oxidative stress.<sup><xref ref-type="bibr" rid="bibr83-1358863X12450094">83</xref>,<xref ref-type="bibr" rid="bibr101-1358863X12450094">101</xref></sup> Randomized trials have established the CV benefits of ACE inhibitors and ARBs in patients with T2DM. Therefore, ACE inhibitors and ARBs are currently recommended for the prevention and treatment of CV diseases in patients with T2DM.</p>
<p>Activation of the AT<sub>1</sub> receptor by Ang II can trigger some of its actions through interaction with and activation of aldosterone-mineralocorticoid receptor signaling.<sup><xref ref-type="bibr" rid="bibr1-1358863X12450094">1</xref></sup> Aldosterone has been shown to upregulate the expression of ACE in cultured neonatal rat cardiomyocytes.<sup><xref ref-type="bibr" rid="bibr102-1358863X12450094">102</xref></sup> Aldosterone excess results in increased ROS production in CV tissues through activation of the membrane-bound NADPH oxidase. It has been shown that aldosterone through stimulating ROS generation inhibits insulin signaling molecules IRS-1 or IRS-2 in 3T3-L1 adipocytes and vascular smooth muscle cells,<sup><xref ref-type="bibr" rid="bibr103-1358863X12450094">103</xref>,<xref ref-type="bibr" rid="bibr104-1358863X12450094">104</xref></sup> as well as glucose-mediated insulin release in murine islets.<sup><xref ref-type="bibr" rid="bibr105-1358863X12450094">105</xref></sup> From a clinical perspective, excess aldosterone is linked to impaired glucose tolerance and T2DM. Current data indicates that up to one-half of patients with primary hyperaldosteronism have impaired glucose tolerance.<sup><xref ref-type="bibr" rid="bibr54-1358863X12450094">54</xref>,<xref ref-type="bibr" rid="bibr76-1358863X12450094">76</xref></sup> Several clinical studies have demonstrated a significant association of aldosterone plasma levels with insulin resistance and there is some evidence that plasma aldosterone levels may be predictive of the development of insulin resistance.<sup><xref ref-type="bibr" rid="bibr106-1358863X12450094">106</xref>,<xref ref-type="bibr" rid="bibr107-1358863X12450094">107</xref></sup> Moreover, insulin resistance is restored by surgical intervention or MR antagonists in primary hyperaldosteronism.<sup><xref ref-type="bibr" rid="bibr108-1358863X12450094">108</xref></sup> Clinical studies in patients with primary hyperaldosteronism have also revealed that excess aldosterone is related to increased cardiac mass, fibrosis, and cardiovascular tissue remodeling relative to those in individuals with essential hypertension.<sup><xref ref-type="bibr" rid="bibr76-1358863X12450094">76</xref></sup> Inhibition of aldosterone by aldosterone synthase inhibitors or MR antagonists improves CV outcomes in patients with CV disease or CV risk factors.<sup><xref ref-type="bibr" rid="bibr109-1358863X12450094">109</xref><xref ref-type="bibr" rid="bibr110-1358863X12450094"/>–<xref ref-type="bibr" rid="bibr111-1358863X12450094">111</xref></sup></p>
<p>A reactive increase in the activity of renin has been observed when either ACE inhibitors or ARBs are used for long periods of time.<sup><xref ref-type="bibr" rid="bibr112-1358863X12450094">112</xref></sup> Renin is a rate-limiting enzyme in RAAS activation. It now appears that renin exerts additional actions through a renin receptor, distinct from its actions that lead to the production of Ang II and aldosterone.<sup><xref ref-type="bibr" rid="bibr113-1358863X12450094">113</xref></sup> It is anticipated that the ability to inhibit renin would improve blood pressure control and might modify other actions and interactions of this important vasoactive system.<sup><xref ref-type="bibr" rid="bibr114-1358863X12450094">114</xref>,<xref ref-type="bibr" rid="bibr115-1358863X12450094">115</xref></sup> Pharmacological inhibition of the renin receptor-dependent system has shown beneficial effects in diabetic nephropathy and retinopathy in diabetic patients and animal models.<sup><xref ref-type="bibr" rid="bibr113-1358863X12450094">113</xref>,<xref ref-type="bibr" rid="bibr116-1358863X12450094">116</xref>,<xref ref-type="bibr" rid="bibr117-1358863X12450094">117</xref></sup> Clinical studies have shown that direct renin inhibition with aliskiren is effective in promoting left ventricle (LV) mass regression in hypertensive patients with LV hypertrophy.<sup><xref ref-type="bibr" rid="bibr118-1358863X12450094">118</xref></sup> Inhibition of renin with aliskiren attenuated systemic insulin resistance, oxidative stress, and pancreatic remodeling and improved skeletal muscle glucose insulin transport in the transgenic renin 2 rats, obese Zucker rats,<sup><xref ref-type="bibr" rid="bibr119-1358863X12450094">119</xref>,<xref ref-type="bibr" rid="bibr120-1358863X12450094">120</xref></sup> suggesting a role of renin in the development of insulin resistance. However, whether inhibition of renin improves insulin resistance in the clinical setting remains to be investigated.</p>
<p>Experimental and clinical studies have established the beneficial effects of RAAS inhibition in CV and metabolic diseases. However, the mechanisms underlying the improvement of insulin resistance and CV injury by RAAS blockade are complex and not fully elucidated. Both Ang II and aldosterone stimulate release of inflammatory cytokines and ROS production, leading to inhibition of insulin signaling and endothelial dysfunction. The mechanisms that have been proposed include stimulation of intracellular insulin signaling in insulin-sensitive and CV tissues,<sup><xref ref-type="bibr" rid="bibr13-1358863X12450094">13</xref>,<xref ref-type="bibr" rid="bibr75-1358863X12450094">75</xref></sup> improvement of microvascular endothelial function leading to increased blood flow and glucose delivery and disposal in skeletal muscle,<sup><xref ref-type="bibr" rid="bibr12-1358863X12450094">12</xref></sup> improvement of pancreatic β-cell function resulting in enhanced insulin secretion in response to glucose stimulation,<sup><xref ref-type="bibr" rid="bibr46-1358863X12450094">46</xref></sup> and modulation of adipose tissue hormonal responses<sup><xref ref-type="bibr" rid="bibr121-1358863X12450094">121</xref></sup> (<xref ref-type="fig" rid="fig4-1358863X12450094">Figure 4</xref>).</p>
<fig id="fig4-1358863X12450094" position="float">
<label>Figure 4.</label>
<caption>
<p>Schemata of potential mechanisms underlying the improvement of insulin resistance and prevention of diabetes development by inhibition of the renin–angiotensin–aldosterone system (RAAS). In the RAAS system, renin cleaves a leucine–valine bond in the angiotensinogen (AGT) molecule to release angiotensin I (Ang I), which is cleaved to Ang II by angiotensin-converting enzyme (ACE). Ang II induces aldosterone release and other biological effects though activation of the AT1 receptor. Activation of Ang II and aldosterone produces the following major biological effects: (1) inhibition of insulin activation of the insulin receptor substrate-1 (IRS-1)/phosphatidylinositol 3-kinase (PI3K) signaling pathway through increased inflammatory cytokine release in insulin-sensitive tissues and cardiovascular (CV) system; (2) inhibition of pre-adipocyte differentiation into mature adipocytes, leading to an increase in secretion of diabetic adipokines and a decrease in antidiabetic adipokines; (3) increased reactive oxygen species (ROS) production, resulting in islet cell structural damage, β-cell dysfunction and endothelial cell dysfunction; and (4) activation of the mitogen-activated protein kinase (MAPK) pathway, leading to vascular remodeling and promotion of CV disease (CVD). All of these biological effects cause impairment of glucose metabolism and insulin resistance, thus contributing to the development of diabetes. Inhibition of RAAS, including renin inhibitors, ACE inhibitors (ACEI), angiotensin II type 1 receptor blockers (ARBs), aldosterone synthase inhibitors and mineralocorticoid receptor (MR) antagonists, prevents these detrimental effects of Ang II and/or aldosterone on glucose metabolism, therefore improving insulin sensitivity, and potentially reducing the development of diabetes and CV complications.</p>
</caption>
<graphic xlink:href="10.1177_1358863X12450094-fig4.tif"/></fig>
</sec>
<sec id="section13-1358863X12450094" sec-type="conclusions">
<title>Conclusion</title>
<p>Approximately 25% of adults in the USA have been diagnosed with the metabolic syndrome. Individuals with the metabolic syndrome have an increased risk of coronary artery disease, which translates into a 2.6-fold increase in CV mortality. Accumulating experimental evidence indicates that activation of the RAAS is critical for the development of insulin resistance, glucose intolerance, T2DM, hypertension, and other CV diseases.<sup><xref ref-type="bibr" rid="bibr5-1358863X12450094">5</xref>,<xref ref-type="bibr" rid="bibr9-1358863X12450094">9</xref>,<xref ref-type="bibr" rid="bibr49-1358863X12450094">49</xref>,<xref ref-type="bibr" rid="bibr71-1358863X12450094">71</xref></sup> Further research is necessary to identify patients at risk for the development of T2DM and other CV complications and those who would most benefit from RAAS blockade.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was supported by an American Heart Association National Scientist Development Award and Florida JEK Biomedical Research grant to Ming-Sheng Zhou.</p></fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1358863X12450094">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lastra</surname><given-names>G</given-names></name>
<name><surname>Dhuper</surname><given-names>S</given-names></name>
<name><surname>Johnson</surname><given-names>MS</given-names></name>
<name><surname>Sowers</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Salt, aldosterone, and insulin resistance: Impact on the cardiovascular system</article-title>. <source>Nat Rev Cardiol</source> <year>2010</year>; <volume>7</volume>: <fpage>577</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr2-1358863X12450094">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alberti</surname><given-names>KG</given-names></name>
<name><surname>Zimmet</surname><given-names>P</given-names></name>
<name><surname>Shaw</surname><given-names>J</given-names></name>
</person-group>. <article-title>The metabolic syndrome—a new worldwide definition</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>: <fpage>1059</fpage>–<lpage>1062</lpage>.</citation>
</ref>
<ref id="bibr3-1358863X12450094">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Filippo</surname><given-names>G</given-names></name>
<name><surname>Rendina</surname><given-names>D</given-names></name>
<name><surname>Strazzullo</surname><given-names>P</given-names></name>
</person-group>. <article-title>Childhood obesity, other cardiovascular risk factors, and premature death</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <year>1841</year>.</citation>
</ref>
<ref id="bibr4-1358863X12450094">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schulman</surname><given-names>IH</given-names></name>
<name><surname>Zhou</surname><given-names>MS</given-names></name>
</person-group>. <article-title>Vascular insulin resistance: A potential link between cardiovascular and metabolic diseases</article-title>. <source>Curr Hypertens Rep</source> <year>2009</year>; <volume>11</volume>: <fpage>48</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr5-1358863X12450094">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cooper</surname><given-names>SA</given-names></name>
<name><surname>Whaley-Connell</surname><given-names>A</given-names></name>
<name><surname>Habibi</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance</article-title>. <source>Am J Physiol</source> <year>2007</year>; <volume>293</volume>: <fpage>H2009</fpage>–<lpage>2023</lpage>.</citation>
</ref>
<ref id="bibr6-1358863X12450094">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andreozzi</surname><given-names>F</given-names></name>
<name><surname>Laratta</surname><given-names>E</given-names></name>
<name><surname>Sciacqua</surname><given-names>A</given-names></name>
<name><surname>Perticone</surname><given-names>F</given-names></name>
<name><surname>Sesti</surname><given-names>G</given-names></name>
</person-group>. <article-title>Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser(312) and Ser(616) in human umbilical vein endothelial cells</article-title>. <source>Circ Res</source> <year>2004</year>; <volume>94</volume>: <fpage>1211</fpage>–<lpage>1218</lpage>.</citation>
</ref>
<ref id="bibr7-1358863X12450094">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Folli</surname><given-names>F</given-names></name>
<name><surname>Kahn</surname><given-names>CR</given-names></name>
<name><surname>Hansen</surname><given-names>H</given-names></name>
<name><surname>Bouchie</surname><given-names>JL</given-names></name>
<name><surname>Feener</surname><given-names>EP</given-names></name>
</person-group>. <article-title>Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels – A potential role for serine phosphorylation in insulin/angiotensin II crosstalk</article-title>. <source>J Clin Invest</source> <year>1997</year>; <volume>100</volume>: <fpage>2158</fpage>–<lpage>2169</lpage>.</citation>
</ref>
<ref id="bibr8-1358863X12450094">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>ZY</given-names></name>
<name><surname>Lin</surname><given-names>YW</given-names></name>
<name><surname>Clemont</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats</article-title>. <source>J Clin Invest</source> <year>1999</year>; <volume>104</volume>: <fpage>447</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr9-1358863X12450094">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Schulman</surname><given-names>IH</given-names></name>
<name><surname>Raij</surname><given-names>L</given-names></name>
</person-group>. <article-title>Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension</article-title>. <source>Am J Physiol</source> <year>2009</year>; <volume>296</volume>: <fpage>H833</fpage>–<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr10-1358863X12450094">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andraws</surname><given-names>R</given-names></name>
<name><surname>Brown</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials)</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>99</volume>: <fpage>1006</fpage>–<lpage>1012</lpage>.</citation>
</ref>
<ref id="bibr11-1358863X12450094">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yavuz</surname><given-names>D</given-names></name>
<name><surname>Koðc</surname><given-names>M</given-names></name>
<name><surname>Toprak</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Effects of ACE inhibition and AT1-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2003</year>; <volume>4</volume>: <fpage>197</fpage>–<lpage>203</lpage>.</citation>
</ref>
<ref id="bibr12-1358863X12450094">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JA</given-names></name>
<name><surname>Montagnani</surname><given-names>M</given-names></name>
<name><surname>Koh</surname><given-names>KK</given-names></name>
<name><surname>Quon</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Reciprocal relationships between insulin resistance and endothelial dysfunction: Molecular and pathophysiological mechanisms</article-title>. <source>Circulation</source> <year>2006</year>; <volume>113</volume>: <fpage>1888</fpage>–<lpage>1904</lpage>.</citation>
</ref>
<ref id="bibr13-1358863X12450094">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Schulman</surname><given-names>IH</given-names></name>
</person-group>. <article-title>Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial</article-title>. <source>Vasc Health Risk Manag</source> <year>2009</year>; <volume>5</volume>: <fpage>361</fpage>–<lpage>368</lpage>.</citation>
</ref>
<ref id="bibr14-1358863X12450094">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muniyappa</surname><given-names>R</given-names></name>
<name><surname>Montagnani</surname><given-names>M</given-names></name>
<name><surname>Koh</surname><given-names>KK</given-names></name>
<name><surname>Quon</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Cardiovascular actions of insulin</article-title>. <source>Endocr Rev</source> <year>2007</year>; <volume>28</volume>: <fpage>463</fpage>–<lpage>491</lpage>.</citation>
</ref>
<ref id="bibr15-1358863X12450094">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stump</surname><given-names>CS</given-names></name>
<name><surname>Henriksen</surname><given-names>EJ</given-names></name>
<name><surname>Wei</surname><given-names>Y</given-names></name>
<name><surname>Sowers</surname><given-names>JR</given-names></name>
</person-group>. <article-title>The metabolic syndrome: Role of skeletal muscle metabolism</article-title>. <source>Ann Med</source> <year>2006</year>; <volume>38</volume>: <fpage>389</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr16-1358863X12450094">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinberg</surname><given-names>HO</given-names></name>
<name><surname>Brechtel</surname><given-names>G</given-names></name>
<name><surname>Johnson</surname><given-names>A</given-names></name>
<name><surname>Fineberg</surname><given-names>N</given-names></name>
<name><surname>Baron</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release</article-title>. <source>J Clin Invest</source> <year>1994</year>; <volume>94</volume>: <fpage>1172</fpage>–<lpage>1179</lpage>.</citation>
</ref>
<ref id="bibr17-1358863X12450094">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nistala</surname><given-names>R</given-names></name>
<name><surname>Stump</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Skeletal muscle insulin resistance is fundamental to the cardiometabolic syndrome</article-title>. <source>J Cardiometab Syndr</source> <year>2006</year>; <volume>1</volume>: <fpage>47</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr18-1358863X12450094">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baron</surname><given-names>AD</given-names></name>
<name><surname>Brechtel-Hook</surname><given-names>G</given-names></name>
<name><surname>Johnson</surname><given-names>A</given-names></name>
<name><surname>Cronin</surname><given-names>J</given-names></name>
<name><surname>Leaming</surname><given-names>R</given-names></name>
<name><surname>Steinberg</surname><given-names>HO</given-names></name>
</person-group>. <article-title>Effect of perfusion rate on the time course of insulin-mediated skeletal muscle glucose uptake</article-title>. <source>Am J Physiol</source> <year>1996</year>; <volume>271</volume>: <fpage>E1067</fpage>–<lpage>1072</lpage>.</citation>
</ref>
<ref id="bibr19-1358863X12450094">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scherrer</surname><given-names>U</given-names></name>
<name><surname>Sartori</surname><given-names>C</given-names></name>
</person-group>. <article-title>Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity</article-title>. <source>Circulation</source> <year>1997</year>; <volume>96</volume>: <fpage>4104</fpage>–<lpage>4113</lpage>.</citation>
</ref>
<ref id="bibr20-1358863X12450094">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cardillo</surname><given-names>C</given-names></name>
<name><surname>Nambi</surname><given-names>SS</given-names></name>
<name><surname>Kilcoyne</surname><given-names>CM</given-names></name>
<etal/>
</person-group>. <article-title>Insulin stimulates both endothelin and nitric oxide activity in the human forearm</article-title>. <source>Circulation</source> <year>1999</year>; <volume>100</volume>: <fpage>820</fpage>–<lpage>825</lpage>.</citation>
</ref>
<ref id="bibr21-1358863X12450094">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dandona</surname><given-names>P</given-names></name>
<name><surname>Aljada</surname><given-names>A</given-names></name>
<name><surname>O’Donnell</surname><given-names>A</given-names></name>
<name><surname>Dhindsa</surname><given-names>S</given-names></name>
<name><surname>Garg</surname><given-names>R</given-names></name>
</person-group>. <article-title>Insulin is an anti-inflammatory and anti-atherosclerotic hormone</article-title>. <source>Metab Syndr Relat Disord</source> <year>2004</year>; <volume>2</volume>: <fpage>137</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr22-1358863X12450094">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Schulman</surname><given-names>IH</given-names></name>
<name><surname>Raij</surname><given-names>L</given-names></name>
</person-group>. <article-title>Nitric oxide, angiotensin II, and hypertension</article-title>. <source>Semin Nephrol</source> <year>2004</year>; <volume>24</volume>: <fpage>366</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr23-1358863X12450094">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Wu</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Insulin inhibits tumor necrosis factor-alpha induction in myocardial ischemia/reperfusion: Role of Akt and endothelial nitric oxide synthase phosphorylation</article-title>. <source>Crit Care Med</source> <year>2008</year>; <volume>36</volume>: <fpage>1551</fpage>–<lpage>1558</lpage>.</citation>
</ref>
<ref id="bibr24-1358863X12450094">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dandona</surname><given-names>P</given-names></name>
<name><surname>Chaudhuri</surname><given-names>A</given-names></name>
<name><surname>Ghanim</surname><given-names>H</given-names></name>
<name><surname>Mohanty</surname><given-names>P</given-names></name>
</person-group>. <article-title>Proinflammatory effects of glucose and anti-inflammatory effect of insulin: Relevance to cardiovascular disease</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>99</volume>: <fpage>15B</fpage>–<lpage>26B</lpage>.</citation>
</ref>
<ref id="bibr25-1358863X12450094">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chaudhuri</surname><given-names>A</given-names></name>
<name><surname>Janicke</surname><given-names>D</given-names></name>
<name><surname>Wilson</surname><given-names>MF</given-names></name>
<etal/>
</person-group>. <article-title>Anti-inflammatory and profibrinolytic effect of insulin in acute ST-segment-elevation myocardial infarction</article-title>. <source>Circulation</source> <year>2004</year>; <volume>109</volume>: <fpage>849</fpage>–<lpage>854</lpage>.</citation>
</ref>
<ref id="bibr26-1358863X12450094">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shamir</surname><given-names>R</given-names></name>
<name><surname>Shehadeh</surname><given-names>N</given-names></name>
<name><surname>Rosenblat</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2003</year>; <volume>23</volume>: <fpage>104</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr27-1358863X12450094">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dandona</surname><given-names>P</given-names></name>
<name><surname>Aljada</surname><given-names>A</given-names></name>
<name><surname>Chaudhuri</surname><given-names>A</given-names></name>
<name><surname>Mohanty</surname><given-names>P</given-names></name>
<name><surname>Garg</surname><given-names>R</given-names></name>
</person-group>. <article-title>Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation</article-title>. <source>Circulation</source> <year>2005</year>; <volume>111</volume>: <fpage>1448</fpage>–<lpage>1454</lpage>.</citation>
</ref>
<ref id="bibr28-1358863X12450094">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dandona</surname><given-names>P</given-names></name>
<name><surname>Chaudhuri</surname><given-names>A</given-names></name>
<name><surname>Ghanim</surname><given-names>H</given-names></name>
<name><surname>Mohanty</surname><given-names>P</given-names></name>
</person-group>. <article-title>Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose</article-title>. <source>Rev Cardiovasc Med</source> <year>2006</year>; <volume>18</volume>: <fpage>293</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr29-1358863X12450094">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>C</given-names></name>
<name><surname>Noordeloos</surname><given-names>AM</given-names></name>
<name><surname>Jeney</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Heme oxygenase 1 determines atherosclerotic lesion progression into a vulnerable plaque</article-title>. <source>Circulation</source> <year>2009</year>; <volume>119</volume>: <fpage>3017</fpage>–<lpage>3027</lpage>.</citation>
</ref>
<ref id="bibr30-1358863X12450094">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ishikawa</surname><given-names>K</given-names></name>
<name><surname>Sugawara</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice</article-title>. <source>Circ Res</source> <year>2001</year>; <volume>88</volume>: <fpage>506</fpage>–<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr31-1358863X12450094">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geraldes</surname><given-names>P</given-names></name>
<name><surname>Yagi</surname><given-names>K</given-names></name>
<name><surname>Ohshiro</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Selective regulation of heme oxygenase-1 expression and function by insulin through IRS1/phosphoinositide 3-kinase/Akt-2 pathway</article-title>. <source>J Biol Chem</source> <year>2008</year>; <volume>283</volume>: <fpage>34,327</fpage>–<lpage>34,336</lpage>.</citation>
</ref>
<ref id="bibr32-1358863X12450094">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>EM</given-names></name>
<name><surname>McNally</surname><given-names>SJ</given-names></name>
<name><surname>Devey</surname><given-names>L</given-names></name>
<name><surname>Garden</surname><given-names>OJ</given-names></name>
<name><surname>Ross</surname><given-names>JA</given-names></name>
<name><surname>Wigmore</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Insulin induces heme oxygenase-1 through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in renal cells</article-title>. <source>FEBS J</source> <year>2006</year>; <volume>273</volume>: <fpage>2345</fpage>–<lpage>2356</lpage>.</citation>
</ref>
<ref id="bibr33-1358863X12450094">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xi</surname><given-names>XP</given-names></name>
<name><surname>Graf</surname><given-names>K</given-names></name>
<name><surname>Goetze</surname><given-names>S</given-names></name>
<name><surname>Hsueh</surname><given-names>WA</given-names></name>
<name><surname>Law</surname><given-names>RE</given-names></name>
</person-group>. <article-title>Inhibition of MAP kinase blocks insulin-mediated DNA synthesis and transcriptional activation of c-fos by Elk-1 in vascular smooth muscle cells</article-title>. <source>FEBS Lett</source> <year>1997</year>; <volume>417</volume>: <fpage>283</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr34-1358863X12450094">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dandona</surname><given-names>P</given-names></name>
<name><surname>Aljada</surname><given-names>A</given-names></name>
<name><surname>Chaudhuri</surname><given-names>A</given-names></name>
<name><surname>Bandyopadhyay</surname><given-names>A</given-names></name>
</person-group>. <article-title>The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes</article-title>. <source>J Clin Endocrinol Metab</source> <year>2003</year>; <volume>88</volume>: <fpage>2422</fpage>–<lpage>2429</lpage>.</citation>
</ref>
<ref id="bibr35-1358863X12450094">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nigro</surname><given-names>J</given-names></name>
<name><surname>Osman</surname><given-names>N</given-names></name>
<name><surname>Dart</surname><given-names>AM</given-names></name>
<name><surname>Little</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>Insulin resistance and atherosclerosis</article-title>. <source>Endocr Rev</source> <year>2006</year>; <volume>27</volume>: <fpage>242</fpage>–<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr36-1358863X12450094">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boyle</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>Diabetes mellitus and macrovascular disease: Mechanisms and mediators</article-title>. <source>Am J Med</source> <year>2007</year>; <volume>120</volume> (<supplement>Suppl 2</supplement>): <fpage>S12</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr37-1358863X12450094">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tuck</surname><given-names>ML</given-names></name>
<name><surname>Bounoua</surname><given-names>F</given-names></name>
<name><surname>Eslami</surname><given-names>P</given-names></name>
<name><surname>Nyby</surname><given-names>MD</given-names></name>
<name><surname>Eggena</surname><given-names>P</given-names></name>
<name><surname>Corry</surname><given-names>DB</given-names></name>
</person-group>. <article-title>Insulin stimulates endogenous angiotensin II production via a mitogen-activated protein kinase pathway in vascular smooth muscle cells</article-title>. <source>J Hypertens</source> <year>2004</year>; <volume>22</volume>: <fpage>1779</fpage>–<lpage>1785</lpage>.</citation>
</ref>
<ref id="bibr38-1358863X12450094">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamide</surname><given-names>K</given-names></name>
<name><surname>Rakugi</surname><given-names>H</given-names></name>
<name><surname>Nagai</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Insulin-mediated regulation of the endothelial renin-angiotensin system and vascular cell growth</article-title>. <source>J Hypertens</source> <year>2004</year>; <volume>22</volume>: <fpage>121</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr39-1358863X12450094">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lopaschuk</surname><given-names>GD</given-names></name>
<name><surname>Ussher</surname><given-names>JR</given-names></name>
<name><surname>Folmes</surname><given-names>CD</given-names></name>
<name><surname>Jaswal</surname><given-names>JS</given-names></name>
<name><surname>Stanley</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Myocardial fatty acid metabolism in health and disease</article-title>. <source>Physiol Rev</source> <year>2010</year>; <volume>90</volume>: <fpage>207</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr40-1358863X12450094">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furumoto</surname><given-names>T</given-names></name>
<name><surname>Fujii</surname><given-names>S</given-names></name>
<name><surname>Onozuka</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Loss of insulin receptor substrate-1 signaling induces the cardiovascular and proteo(fibrino)lytic system derangements typical of insulin resistance</article-title>. <source>Coron Artery Dis</source> <year>2005</year>; <volume>16</volume>: <fpage>117</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr41-1358863X12450094">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rohini</surname><given-names>A</given-names></name>
<name><surname>Agrawal</surname><given-names>N</given-names></name>
<name><surname>Koyani</surname><given-names>CN</given-names></name>
<name><surname>Singh</surname><given-names>R</given-names></name>
</person-group>. <article-title>Molecular targets and regulators of cardiac hypertrophy</article-title>. <source>Pharmacol Res</source> <year>2010</year>; <volume>61</volume>: <fpage>269</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr42-1358863X12450094">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kinugawa</surname><given-names>S</given-names></name>
<name><surname>Tsutsui</surname><given-names>H</given-names></name>
<name><surname>Ide</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes</article-title>. <source>Cardiovasc Res</source> <year>1999</year>; <volume>43</volume>: <fpage>157</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr43-1358863X12450094">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tikellis</surname><given-names>C</given-names></name>
<name><surname>Bernardi</surname><given-names>S</given-names></name>
<name><surname>Burns</surname><given-names>WC</given-names></name>
</person-group>. <article-title>Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease</article-title>. <source>Curr Opin Nephrol Hypertens</source> <year>2011</year>; <volume>20</volume>: <fpage>62</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr44-1358863X12450094">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Briet</surname><given-names>M</given-names></name>
<name><surname>Schiffrin</surname><given-names>EL</given-names></name>
</person-group>. <article-title>Aldosterone: Effects on the kidney and cardiovascular system</article-title>. <source>Nat Rev Nephrol</source> <year>2010</year>; <volume>6</volume>: <fpage>261</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr45-1358863X12450094">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schulman</surname><given-names>IH</given-names></name>
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Raij</surname><given-names>L</given-names></name>
</person-group>. <article-title>Nitric oxide, angiotensin II, and reactive oxygen species in hypertension and atherogenesis</article-title>. <source>Curr Hypertens Rep</source> <year>2005</year>; <volume>7</volume>: <fpage>61</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr46-1358863X12450094">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>MH</given-names></name>
<name><surname>Song</surname><given-names>HK</given-names></name>
<name><surname>Ko</surname><given-names>GJ</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue</article-title>. <source>Kidney Int</source> <year>2008</year>; <volume>74</volume>: <fpage>890</fpage>–<lpage>900</lpage>.</citation>
</ref>
<ref id="bibr47-1358863X12450094">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shoelson</surname><given-names>SE</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Goldfine</surname><given-names>AB</given-names></name>
</person-group>. <article-title>Inflammation and insulin resistance</article-title>. <source>J Clin Invest</source> <year>2006</year>; <volume>116</volume>: <fpage>1793</fpage>–<lpage>1801</lpage>.</citation>
</ref>
<ref id="bibr48-1358863X12450094">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname><given-names>Y</given-names></name>
<name><surname>Sowers</surname><given-names>JR</given-names></name>
<name><surname>Clark</surname><given-names>SE</given-names></name>
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Ferrario</surname><given-names>CM</given-names></name>
<name><surname>Stump</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase</article-title>. <source>Am J Physiol</source> <year>2008</year>; <volume>294</volume>: <fpage>E345</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr49-1358863X12450094">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname><given-names>Y</given-names></name>
<name><surname>Sowers</surname><given-names>JR</given-names></name>
<name><surname>Nistala</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells</article-title>. <source>J Biol Chem</source> <year>2006</year>; <volume>281</volume>: <fpage>35,137</fpage>–<lpage>35,146</lpage>.</citation>
</ref>
<ref id="bibr50-1358863X12450094">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mullins</surname><given-names>JJ</given-names></name>
<name><surname>Peters</surname><given-names>J</given-names></name>
<name><surname>Ganten</surname><given-names>D</given-names></name>
</person-group>. <article-title>Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene</article-title>. <source>Nature</source> <year>1990</year>; <volume>344</volume>: <fpage>541</fpage>–<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr51-1358863X12450094">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blendea</surname><given-names>MC</given-names></name>
<name><surname>Jacobs</surname><given-names>D</given-names></name>
<name><surname>Stump</surname><given-names>CS</given-names></name>
<etal/>
</person-group>. <article-title>Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression</article-title>. <source>Am J Physiol Endocrinol Metab</source> <year>2005</year>; <volume>288</volume>: <fpage>E353</fpage>–<lpage>E359</lpage>.</citation>
</ref>
<ref id="bibr52-1358863X12450094">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sloniger</surname><given-names>JA</given-names></name>
<name><surname>Saengsirisuwan</surname><given-names>V</given-names></name>
<name><surname>Diehl</surname><given-names>CJ</given-names></name>
<etal/>
</person-group>. <article-title>Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat</article-title>. <source>Am J Physiol Endocrinol Metab</source> <year>2005</year>; <volume>288</volume>: <fpage>E1074</fpage>–<lpage>E1081</lpage>.</citation>
</ref>
<ref id="bibr53-1358863X12450094">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gillespie</surname><given-names>EL</given-names></name>
<name><surname>White</surname><given-names>CM</given-names></name>
<name><surname>Kardas</surname><given-names>M</given-names></name>
<name><surname>Lindberg</surname><given-names>M</given-names></name>
<name><surname>Coleman</surname><given-names>CI</given-names></name>
</person-group>. <article-title>The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes</article-title>. <source>Diabetes Care</source> <year>2005</year>; <volume>28</volume>: <fpage>2261</fpage>–<lpage>2266</lpage>.</citation>
</ref>
<ref id="bibr54-1358863X12450094">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lastra</surname><given-names>G</given-names></name>
<name><surname>Sowers</surname><given-names>JR</given-names></name>
<name><surname>Restrepo-Erazo</surname><given-names>K</given-names></name>
<name><surname>Manrique-Acevedo</surname><given-names>C</given-names></name>
<name><surname>Lastra-Gonzâalez</surname><given-names>G</given-names></name>
</person-group>. <article-title>Role of aldosterone and angiotensin II in insulin resistance: An update</article-title>. <source>Clin Endocrinol</source> <year>2009</year>; <volume>71</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr55-1358863X12450094">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kjeldsen</surname><given-names>SE</given-names></name>
<name><surname>Julius</surname><given-names>S</given-names></name>
<name><surname>Mancia</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial</article-title>. <source>J Hypertens</source> <year>2006</year>; <volume>24</volume>: <fpage>1405</fpage>–<lpage>1412</lpage>.</citation>
</ref>
<ref id="bibr56-1358863X12450094">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perlstein</surname><given-names>T</given-names></name>
<name><surname>Henry</surname><given-names>P</given-names></name>
<name><surname>Mather</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Effects of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose</article-title>. <source>Clin Sci (Lond)</source> <year>2012</year>; <volume>122</volume>: <fpage>193</fpage>–<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr57-1358863X12450094">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Laakso</surname><given-names>M</given-names></name>
<name><surname>Karjalainen</surname><given-names>L</given-names></name>
<name><surname>Lempiainen-Kuosa</surname><given-names>P</given-names></name>
</person-group>. <article-title>Effects of losartan on insulin sensitivity in hypertensive subjects</article-title>. <source>Hypertension</source> <year>1996</year>; <volume>28</volume>: <fpage>392</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr58-1358863X12450094">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lteif</surname><given-names>AA</given-names></name>
<name><surname>Chisholm</surname><given-names>R</given-names></name>
<name><surname>Gilbert</surname><given-names>K</given-names></name>
<name><surname>Considine</surname><given-names>R</given-names></name>
<name><surname>Mather</surname><given-names>K</given-names></name>
</person-group>. <article-title>Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity/insulin resistance without hypertension</article-title>. <source>Diabetes Obes Metab</source> <year>2012</year>; <volume>14</volume>: <fpage>254</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr59-1358863X12450094">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Gaal</surname><given-names>LF</given-names></name>
<name><surname>Mertens</surname><given-names>IL</given-names></name>
<name><surname>De Block</surname><given-names>CE</given-names></name>
</person-group>. <article-title>Mechanisms linking obesity with cardiovascular disease</article-title>. <source>Nature</source> <year>2006</year>; <volume>444</volume>: <fpage>875</fpage>–<lpage>880</lpage>.</citation>
</ref>
<ref id="bibr60-1358863X12450094">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lumeng</surname><given-names>CN</given-names></name>
<name><surname>Bodzin</surname><given-names>JL</given-names></name>
<name><surname>Saltiel</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Obesity induces a phenotypic switch in adipose tissue macrophage polarization</article-title>. <source>J Clin Invest</source> <year>2007</year>; <volume>117</volume>: <fpage>175</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr61-1358863X12450094">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>K</given-names></name>
<name><surname>Kusminski</surname><given-names>CM</given-names></name>
<name><surname>Scherer</surname><given-names>PE</given-names></name>
</person-group>. <article-title>Adipose tissue remodeling and obesity</article-title>. <source>J Clin Invest</source> <year>2011</year>; <volume>121</volume>: <fpage>2094</fpage>–<lpage>2101</lpage>.</citation>
</ref>
<ref id="bibr62-1358863X12450094">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Engeli</surname><given-names>S</given-names></name>
<name><surname>Negrel</surname><given-names>R</given-names></name>
<name><surname>Sharma</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Physiology and pathophysiology of the adipose tissue renin-angiotensin system</article-title>. <source>Hypertension</source> <year>2000</year>; <volume>35</volume>: <fpage>1270</fpage>–<lpage>1277</lpage>.</citation>
</ref>
<ref id="bibr63-1358863X12450094">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Engeli</surname><given-names>S</given-names></name>
<name><surname>Sharma</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Role of adipose tissue for cardiovascular-renal regulation in health and disease</article-title>. <source>Horm Metab Res</source> <year>2000</year>; <volume>32</volume>: <fpage>485</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr64-1358863X12450094">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>AM</given-names></name>
<name><surname>Janke</surname><given-names>J</given-names></name>
<name><surname>Gorzelniak</surname><given-names>K</given-names></name>
<name><surname>Engeli</surname><given-names>S</given-names></name>
<name><surname>Luft</surname><given-names>FC</given-names></name>
</person-group>. <article-title>Angiotensin blockade prevents type 2 diabetes by formation of fat cells</article-title>. <source>Hypertension</source> <year>2002</year>; <volume>40</volume>: <fpage>609</fpage>–<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr65-1358863X12450094">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruggenenti</surname><given-names>P</given-names></name>
<name><surname>Cattaneo</surname><given-names>D</given-names></name>
<name><surname>Loriga</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: Effects of acetyl-L-carnitine therapy</article-title>. <source>Hypertension</source> <year>2009</year>; <volume>54</volume>: <fpage>567</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr66-1358863X12450094">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Gu</surname><given-names>D</given-names></name>
<name><surname>Huang</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: A dietary intervention study</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>: <fpage>829</fpage>–<lpage>835</lpage>.</citation>
</ref>
<ref id="bibr67-1358863X12450094">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sowers</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Insulin resistance and hypertension</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <year>2004</year>; <volume>286</volume>: <fpage>H1597</fpage>–<lpage>1602</lpage>.</citation>
</ref>
<ref id="bibr68-1358863X12450094">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinberger</surname><given-names>MH</given-names></name>
<name><surname>Fineberg</surname><given-names>NS</given-names></name>
<name><surname>Fineberg</surname><given-names>SE</given-names></name>
<name><surname>Weinberger</surname><given-names>M</given-names></name>
</person-group>. <article-title>Salt sensitivity, pulse pressure, and death in normal and hypertensive humans</article-title>. <source>Hypertension</source> <year>2001</year>; <volume>37</volume>: <fpage>429</fpage>–<lpage>432</lpage>.</citation>
</ref>
<ref id="bibr69-1358863X12450094">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Adam</surname><given-names>AG</given-names></name>
<name><surname>Jaimes</surname><given-names>EA</given-names></name>
<name><surname>Raij</surname><given-names>L</given-names></name>
</person-group>. <article-title>In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>42</volume>: <fpage>945</fpage>–<lpage>951</lpage>.</citation>
</ref>
<ref id="bibr70-1358863X12450094">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Hernandez Schulman</surname><given-names>I</given-names></name>
<name><surname>Pagano</surname><given-names>PJ</given-names></name>
<name><surname>Jaimes</surname><given-names>EA</given-names></name>
<name><surname>Raij</surname><given-names>L</given-names></name>
</person-group>. <article-title>Reduced NAD(P)H oxidase in low renin hypertension: Link among angiotensin II, atherogenesis, and blood pressure</article-title>. <source>Hypertension</source> <year>2006</year>; <volume>47</volume>: <fpage>81</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr71-1358863X12450094">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Schulman</surname><given-names>IH</given-names></name>
<name><surname>Raij</surname><given-names>L</given-names></name>
</person-group>. <article-title>Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: Role of nuclear factor kappa B activation</article-title>. <source>J Hypertens</source> <year>2010</year>; <volume>28</volume>: <fpage>527</fpage>–<lpage>535</lpage>.</citation>
</ref>
<ref id="bibr72-1358863X12450094">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>MS</given-names></name>
<name><surname>Raij</surname><given-names>L</given-names></name>
</person-group>. <article-title>Cross-talk between nitric oxide and endothelium-derived hyperpolarizing factor: Synergistic interaction?</article-title> <source>J Hypertens</source> <year>2003</year>; <volume>21</volume>: <fpage>1449</fpage>–<lpage>1451</lpage>.</citation>
</ref>
<ref id="bibr73-1358863X12450094">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinberg</surname><given-names>HO</given-names></name>
<name><surname>Chaker</surname><given-names>H</given-names></name>
<name><surname>Leaming</surname><given-names>R</given-names></name>
<name><surname>Johnson</surname><given-names>A</given-names></name>
<name><surname>Brechtel</surname><given-names>G</given-names></name>
<name><surname>Baron</surname><given-names>AD</given-names></name>
</person-group>. <article-title>Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance</article-title>. <source>J Clin Invest</source> <year>1996</year>; <volume>97</volume>: <fpage>2601</fpage>–<lpage>2610</lpage>.</citation>
</ref>
<ref id="bibr74-1358863X12450094">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lteif</surname><given-names>AA</given-names></name>
<name><surname>Han</surname><given-names>K</given-names></name>
<name><surname>Mather</surname><given-names>KJ</given-names></name>
</person-group>. <article-title>Obesity, insulin resistance, and the metabolic syndrome: Determinants of endothelial dysfunction in whites and blacks</article-title>. <source>Circulation</source> <year>2005</year>; <volume>112</volume>: <fpage>32</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr75-1358863X12450094">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shiuchi</surname><given-names>T</given-names></name>
<name><surname>Iwai</surname><given-names>M</given-names></name>
<name><surname>Li</surname><given-names>HS</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice</article-title>. <source>Hypertension</source> <year>2004</year>; <volume>43</volume>: <fpage>1003</fpage>–<lpage>1010</lpage>.</citation>
</ref>
<ref id="bibr76-1358863X12450094">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sowers</surname><given-names>JR</given-names></name>
<name><surname>Whaley-Connell</surname><given-names>A</given-names></name>
<name><surname>Epstein</surname><given-names>M</given-names></name>
</person-group>. <article-title>Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension</article-title>. <source>Ann Intern Med</source> <year>2009</year>; <volume>150</volume>: <fpage>776</fpage>–<lpage>783</lpage>.</citation>
</ref>
<ref id="bibr77-1358863X12450094">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wei</surname><given-names>Y</given-names></name>
<name><surname>Whaley-Connell</surname><given-names>AT</given-names></name>
<name><surname>Chen</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat</article-title>. <source>Hypertension</source> <year>2007</year>; <volume>50</volume>: <fpage>384</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr78-1358863X12450094">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuura</surname><given-names>K</given-names></name>
<name><surname>Hagiwara</surname><given-names>N</given-names></name>
</person-group>. <article-title>The pleiotropic effects of ARB in vascular endothelial progenitor cells</article-title>. <source>Curr Vasc Pharmacol</source> <year>2011</year>; <volume>9</volume>: <fpage>153</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr79-1358863X12450094">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Y</given-names></name>
<name><surname>Fukuda</surname><given-names>N</given-names></name>
<name><surname>Yao</surname><given-names>EH</given-names></name>
<etal/>
</person-group>. <article-title>Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension</article-title>. <source>Am J Hypertens</source> <year>2008</year>; <volume>21</volume>: <fpage>72</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr80-1358863X12450094">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rizos</surname><given-names>CV</given-names></name>
<name><surname>Milionis</surname><given-names>HJ</given-names></name>
<name><surname>Kostapanos</surname><given-names>MS</given-names></name>
<etal/>
</person-group>. <article-title>Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: A 24-week, randomized, open-label, prospective study</article-title>. <source>Clin Ther</source> <year>2010</year>; <volume>32</volume>: <fpage>492</fpage>–<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr81-1358863X12450094">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flammer</surname><given-names>AJ</given-names></name>
<name><surname>Hermann</surname><given-names>F</given-names></name>
<name><surname>Wiesli</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension</article-title>. <source>J Hypertens</source> <year>2007</year>; <volume>25</volume>: <fpage>785</fpage>–<lpage>791</lpage>.</citation>
</ref>
<ref id="bibr82-1358863X12450094">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Steinberger</surname><given-names>J</given-names></name>
<name><surname>Daniels</surname><given-names>SR</given-names></name>
</person-group>. <article-title>Obesity, insulin resistance, diabetes, and cardiovascular risk in children: An American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism)</article-title>. <source>Circulation</source> <year>2003</year>; <volume>107</volume>: <fpage>1448</fpage>–<lpage>1453</lpage>.</citation>
</ref>
<ref id="bibr83-1358863X12450094">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luther</surname><given-names>JM</given-names></name>
<name><surname>Brown</surname><given-names>NJ</given-names></name>
</person-group>. <article-title>The renin-angiotensin-aldosterone system and glucose homeostasis</article-title>. <source>Trends Pharmacol Sci</source> <year>2011</year>; <volume>32</volume>: <fpage>734</fpage>–<lpage>739</lpage>.</citation>
</ref>
<ref id="bibr84-1358863X12450094">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Julius</surname><given-names>S</given-names></name>
<name><surname>Kjeldsen</surname><given-names>SE</given-names></name>
<name><surname>Weber</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial</article-title>. <source>Lancet</source> <year>2004</year>; <volume>363</volume>: <fpage>2022</fpage>–<lpage>2031</lpage>.</citation>
</ref>
<ref id="bibr85-1358863X12450094">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Holman</surname><given-names>RR</given-names></name>
<name><surname>Haffner</surname><given-names>SM</given-names></name>
<etal/>
</person-group>. <article-title>Effect of valsartan on the incidence of diabetes and cardiovascular events</article-title>. <source>N Engl J Med</source> <year>2010</year>; <volume>362</volume>: <fpage>1477</fpage>–<lpage>1490</lpage>.</citation>
</ref>
<ref id="bibr86-1358863X12450094">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barzilay</surname><given-names>JI</given-names></name>
<name><surname>Davis</surname><given-names>BR</given-names></name>
<name><surname>Cutler</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</article-title>. <source>Arch Intern Med</source> <year>2006</year>; <volume>166</volume>: <fpage>2191</fpage>–<lpage>2201</lpage>.</citation>
</ref>
<ref id="bibr87-1358863X12450094">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yusuf</surname><given-names>S</given-names></name>
<name><surname>Sleight</surname><given-names>P</given-names></name>
<name><surname>Pogue</surname><given-names>J</given-names></name>
<name><surname>Bosch</surname><given-names>J</given-names></name>
<name><surname>Davies</surname><given-names>R</given-names></name>
<name><surname>Dagenais</surname><given-names>G</given-names></name>
</person-group>. <article-title>Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators</article-title>. <source>N Engl J Med</source> <year>2000</year>; <volume>342</volume>: <fpage>145</fpage>–<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr88-1358863X12450094">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansson</surname><given-names>L</given-names></name>
<name><surname>Lindholm</surname><given-names>LH</given-names></name>
<name><surname>Niskanen</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial</article-title>. <source>Lancet</source> <year>1999</year>; <volume>353</volume>: <fpage>611</fpage>–<lpage>616</lpage>.</citation>
</ref>
<ref id="bibr89-1358863X12450094">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pfeffer</surname><given-names>MA</given-names></name>
<name><surname>Swedberg</surname><given-names>K</given-names></name>
<name><surname>Granger</surname><given-names>CB</given-names></name>
<etal/>
</person-group>. <article-title>Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme</article-title>. <source>Lancet</source> <year>2003</year>; <volume>362</volume>: <fpage>759</fpage>–<lpage>766</lpage>.</citation>
</ref>
<ref id="bibr90-1358863X12450094">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shindler</surname><given-names>DM</given-names></name>
<name><surname>Kostis</surname><given-names>JB</given-names></name>
<name><surname>Yusuf</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry</article-title>. <source>Am J Cardiol</source> <year>1996</year>; <volume>77</volume>: <fpage>1017</fpage>–<lpage>1020</lpage>.</citation>
</ref>
<ref id="bibr91-1358863X12450094">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Devereux</surname><given-names>RB</given-names></name>
<name><surname>Dahlèof</surname><given-names>B</given-names></name>
<name><surname>Gerdts</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial</article-title>. <source>Circulation</source> <year>2004</year>; <volume>110</volume>: <fpage>1456</fpage>–<lpage>1462</lpage>.</citation>
</ref>
<ref id="bibr92-1358863X12450094">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Julius</surname><given-names>S</given-names></name>
<name><surname>Weber</surname><given-names>MA</given-names></name>
<name><surname>Kjeldsen</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. <article-title>The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: Outcomes in patients receiving monotherapy</article-title>. <source>Hypertension</source> <year>2006</year>; <volume>48</volume>: <fpage>385</fpage>–<lpage>391</lpage>.</citation>
</ref>
<ref id="bibr93-1358863X12450094">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Zannad</surname><given-names>F</given-names></name>
<name><surname>Remme</surname><given-names>WJ</given-names></name>
<etal/>
</person-group>. <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators</article-title>. <source>N Engl J Med</source> <year>1999</year>; <volume>341</volume>: <fpage>709</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr94-1358863X12450094">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bangalore</surname><given-names>S</given-names></name>
<name><surname>Parkar</surname><given-names>S</given-names></name>
<name><surname>Grossman</surname><given-names>E</given-names></name>
<name><surname>Messerli</surname><given-names>FH</given-names></name>
</person-group>. <article-title>A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>100</volume>: <fpage>1254</fpage>–<lpage>1262</lpage>.</citation>
</ref>
<ref id="bibr95-1358863X12450094">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bosch</surname><given-names>J</given-names></name>
<name><surname>Yusuf</surname><given-names>S</given-names></name>
<name><surname>Gerstein</surname><given-names>HC</given-names></name>
<etal/>
</person-group>. <article-title>Effect of ramipril on the incidence of diabetes</article-title>. <source>N Engl J Med</source> <year>2006</year>; <volume>355</volume>: <fpage>1551</fpage>–<lpage>1562</lpage>.</citation>
</ref>
<ref id="bibr96-1358863X12450094">
<label>96.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gerstein</surname><given-names>HC</given-names></name>
<name><surname>Miller</surname><given-names>ME</given-names></name>
<name><surname>Byington</surname><given-names>RP</given-names></name>
<etal/>
</person-group>. <article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>2545</fpage>–<lpage>2559</lpage>.</citation>
</ref>
<ref id="bibr97-1358863X12450094">
<label>97.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>A</given-names></name>
<name><surname>MacMahon</surname><given-names>S</given-names></name>
<name><surname>Chalmers</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>2560</fpage>–<lpage>2572</lpage>.</citation>
</ref>
<ref id="bibr98-1358863X12450094">
<label>98.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ray</surname><given-names>KK</given-names></name>
<name><surname>Seshasai</surname><given-names>SR</given-names></name>
<name><surname>Wijesuriya</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: A meta-analysis of randomised controlled trials</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>: <fpage>1765</fpage>–<lpage>1772</lpage>.</citation>
</ref>
<ref id="bibr99-1358863X12450094">
<label>99.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duckworth</surname><given-names>W</given-names></name>
<name><surname>Abraira</surname><given-names>C</given-names></name>
<name><surname>Moritz</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Glucose control and vascular complications in veterans with type 2 diabetes</article-title>. <source>N Engl J Med</source> <year>2009</year>; <volume>360</volume>: <fpage>129</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr100-1358863X12450094">
<label>100.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pradhan</surname><given-names>AD</given-names></name>
<name><surname>Everett</surname><given-names>BM</given-names></name>
<name><surname>Cook</surname><given-names>NR</given-names></name>
<name><surname>Rifai</surname><given-names>N</given-names></name>
<name><surname>Ridker</surname><given-names>PM</given-names></name>
</person-group>. <article-title>Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: The LANCET randomized trial</article-title>. <source>JAMA</source> <year>2009</year>; <volume>302</volume>: <fpage>1186</fpage>–<lpage>1194</lpage>.</citation>
</ref>
<ref id="bibr101-1358863X12450094">
<label>101.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dandona</surname><given-names>P</given-names></name>
<name><surname>Kumar</surname><given-names>V</given-names></name>
<name><surname>Aljada</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: Evidence of an antiinflammatory action</article-title>. <source>J Clin Endocrinol Metab</source> <year>2003</year>; <volume>88</volume>: <fpage>4496</fpage>–<lpage>4501</lpage>.</citation>
</ref>
<ref id="bibr102-1358863X12450094">
<label>102.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Karmazyn</surname><given-names>M</given-names></name>
<name><surname>Liu</surname><given-names>Q</given-names></name>
<name><surname>Gan</surname><given-names>XT</given-names></name>
<name><surname>Brix</surname><given-names>BJ</given-names></name>
<name><surname>Fliegel</surname><given-names>L</given-names></name>
</person-group>. <article-title>Aldosterone increases NHE-1 expression and induces NHE-1-dependent hypertrophy in neonatal rat ventricular myocytes</article-title>. <source>Hypertension</source> <year>2003</year>; <volume>42</volume>: <fpage>1171</fpage>–<lpage>1176</lpage>.</citation>
</ref>
<ref id="bibr103-1358863X12450094">
<label>103.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wada</surname><given-names>T</given-names></name>
<name><surname>Ohshima</surname><given-names>S</given-names></name>
<name><surname>Fujisawa</surname><given-names>E</given-names></name>
<name><surname>Koya</surname><given-names>D</given-names></name>
<name><surname>Tsuneki</surname><given-names>H</given-names></name>
<name><surname>Sasaoka</surname><given-names>T</given-names></name>
</person-group>. <article-title>Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes</article-title>. <source>Endocrinology</source> <year>2009</year>; <volume>150</volume>: <fpage>1662</fpage>–<lpage>1669</lpage>.</citation>
</ref>
<ref id="bibr104-1358863X12450094">
<label>104.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hitomi</surname><given-names>H</given-names></name>
<name><surname>Kiyomoto</surname><given-names>H</given-names></name>
<name><surname>Nishiyama</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells</article-title>. <source>Hypertension</source> <year>2007</year>; <volume>50</volume>: <fpage>750</fpage>–<lpage>755</lpage>.</citation>
</ref>
<ref id="bibr105-1358863X12450094">
<label>105.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luther</surname><given-names>JM</given-names></name>
<name><surname>Luo</surname><given-names>P</given-names></name>
<name><surname>Kreger</surname><given-names>MT</given-names></name>
<etal/>
</person-group>. <article-title>Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets</article-title>. <source>Diabetologia</source> <year>2011</year>; <volume>54</volume>: <fpage>2152</fpage>–<lpage>2163</lpage>.</citation>
</ref>
<ref id="bibr106-1358863X12450094">
<label>106.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huan</surname><given-names>Y</given-names></name>
<name><surname>Deloach</surname><given-names>S</given-names></name>
<name><surname>Keith</surname><given-names>S</given-names></name>
<name><surname>Goodfriend</surname><given-names>T</given-names></name>
<name><surname>Falkner</surname><given-names>B</given-names></name>
</person-group>. <article-title>Aldosterone and aldosterone:renin ratio associations with insulin resistance and blood pressure in African American</article-title>. <source>J Am Soc Hypertens</source> <year>2012</year>; <volume>6</volume>: <fpage>56</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr107-1358863X12450094">
<label>107.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumagai</surname><given-names>E</given-names></name>
<name><surname>Adachi</surname><given-names>H</given-names></name>
<name><surname>Jacobs</surname><given-names>DJ</given-names></name>
<etal/>
</person-group>. <article-title>Plasma aldosterone levels and development of insulin resistance: Prospective study in a general population</article-title>. <source>Hypertension</source> <year>2011</year>; <volume>58</volume>: <fpage>1043</fpage>–<lpage>1048</lpage>.</citation>
</ref>
<ref id="bibr108-1358863X12450094">
<label>108.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Catena</surname><given-names>C</given-names></name>
<name><surname>Colussi</surname><given-names>G</given-names></name>
<name><surname>Di Fabio</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism</article-title>. <source>Horm Metab Res</source> <year>2010</year>; <volume>42</volume>: <fpage>440</fpage>–<lpage>445</lpage>.</citation>
</ref>
<ref id="bibr109-1358863X12450094">
<label>109.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Reichek</surname><given-names>N</given-names></name>
<name><surname>Willenbrock</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: The 4E-left ventricular hypertrophy study</article-title>. <source>Circulation</source> <year>2003</year>; <volume>108</volume>: <fpage>1831</fpage>–<lpage>1838</lpage>.</citation>
</ref>
<ref id="bibr110-1358863X12450094">
<label>110.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Remme</surname><given-names>W</given-names></name>
<name><surname>Zannad</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</article-title>. <source>N Engl J Med</source> <year>2003</year>; <volume>348</volume>: <fpage>1309</fpage>–<lpage>1321</lpage>.</citation>
</ref>
<ref id="bibr111-1358863X12450094">
<label>111.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossignol</surname><given-names>P</given-names></name>
<name><surname>Mâenard</surname><given-names>J</given-names></name>
<name><surname>Fay</surname><given-names>R</given-names></name>
<name><surname>Gustafsson</surname><given-names>F</given-names></name>
<name><surname>Pitt</surname><given-names>B</given-names></name>
<name><surname>Zannad</surname><given-names>F</given-names></name>
</person-group>. <article-title>Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy</article-title>. <source>J Am Coll Cardiol</source> <year>2011</year>; <volume>58</volume>: <fpage>1958</fpage>–<lpage>1966</lpage>.</citation>
</ref>
<ref id="bibr112-1358863X12450094">
<label>112.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ingelfinger</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Aliskiren and dual therapy in type 2 diabetes mellitus</article-title>. <source>N Eng J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>2503</fpage>–<lpage>2505</lpage>.</citation>
</ref>
<ref id="bibr113-1358863X12450094">
<label>113.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>C</given-names></name>
<name><surname>Herold</surname><given-names>P</given-names></name>
<name><surname>Brunner</surname><given-names>HR</given-names></name>
</person-group>. <article-title>Aliskiren: The first renin inhibitor for clinical treatment</article-title>. <source>Nat Rev Drug Discov</source> <year>2008</year>; <volume>7</volume>: <fpage>399</fpage>–<lpage>410</lpage>.</citation>
</ref>
<ref id="bibr114-1358863X12450094">
<label>114.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oparil</surname><given-names>S</given-names></name>
<name><surname>Yarows</surname><given-names>SA</given-names></name>
<name><surname>Patel</surname><given-names>S</given-names></name>
<name><surname>Fang</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Satlin</surname><given-names>A</given-names></name>
</person-group>. <article-title>Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial</article-title>. <source>Lancet</source> <year>2007</year>; <volume>370</volume>: <fpage>221</fpage>–<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr115-1358863X12450094">
<label>115.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pool</surname><given-names>JL</given-names></name>
<name><surname>Schmieder</surname><given-names>RE</given-names></name>
<name><surname>Azizi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan</article-title>. <source>Am J Hypertens</source> <year>2007</year>; <volume>20</volume>: <fpage>11</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr116-1358863X12450094">
<label>116.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iwai</surname><given-names>M</given-names></name>
<name><surname>Kanno</surname><given-names>H</given-names></name>
<name><surname>Tomono</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-A(y) mice</article-title>. <source>J Hypertens</source> <year>2010</year>; <volume>28</volume>: <fpage>1471</fpage>–<lpage>1481</lpage>.</citation>
</ref>
<ref id="bibr117-1358863X12450094">
<label>117.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parving</surname><given-names>HH</given-names></name>
<name><surname>Persson</surname><given-names>F</given-names></name>
<name><surname>Lewis</surname><given-names>JB</given-names></name>
<name><surname>Lewis</surname><given-names>EJ</given-names></name>
<name><surname>Hollenberg</surname><given-names>NK</given-names></name>
</person-group>. <article-title>Aliskiren combined with losartan in type 2 diabetes and nephropathy</article-title>. <source>N Engl J Med</source> <year>2008</year>; <volume>358</volume>: <fpage>2433</fpage>–<lpage>2446</lpage>.</citation>
</ref>
<ref id="bibr118-1358863X12450094">
<label>118.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solomon</surname><given-names>SD</given-names></name>
<name><surname>Appelbaum</surname><given-names>E</given-names></name>
<name><surname>Manning</surname><given-names>WJ</given-names></name>
<etal/>
</person-group>. <article-title>Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy</article-title>. <source>Circulation</source> <year>2009</year>; <volume>119</volume>: <fpage>530</fpage>–<lpage>537</lpage>.</citation>
</ref>
<ref id="bibr119-1358863X12450094">
<label>119.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lastra</surname><given-names>G</given-names></name>
<name><surname>Habibi</surname><given-names>J</given-names></name>
<name><surname>Whaley-Connell</surname><given-names>AT</given-names></name>
<etal/>
</person-group>. <article-title>Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression</article-title>. <source>Endocrinology</source> <year>2009</year>; <volume>150</volume>: <fpage>2561</fpage>–<lpage>2568</lpage>.</citation>
</ref>
<ref id="bibr120-1358863X12450094">
<label>120.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marchionne</surname><given-names>EM</given-names></name>
<name><surname>Diamond-Stanic</surname><given-names>MK</given-names></name>
<name><surname>Prasonnarong</surname><given-names>M</given-names></name>
<name><surname>Henriksen</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity and skeletal muscle glucose transport activity in obese Zucker rats</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source> <year>2012</year>; <volume>302</volume>: <fpage>R137</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr121-1358863X12450094">
<label>121.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tikellis</surname><given-names>C</given-names></name>
<name><surname>Wookey</surname><given-names>PJ</given-names></name>
<name><surname>Candido</surname><given-names>R</given-names></name>
<name><surname>Andrikopoulos</surname><given-names>S</given-names></name>
<name><surname>Thomas</surname><given-names>MC</given-names></name>
<name><surname>Cooper</surname><given-names>ME</given-names></name>
</person-group>. <article-title>Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat</article-title>. <source>Diabetes</source> <year>2004</year>; <volume>53</volume>: <fpage>989</fpage>–<lpage>997</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>